NewzIntel.com

Category: Health

  • MIL-OSI United Nations: 8 May 2025 Departmental update WHO releases global action plan to strengthen clinical trial ecosystems

    Source: World Health Organisation

    The World Health Organization (WHO) has published the Global action plan for clinical trial ecosystem strengthening (GAP-CTS), a key implementation tool aligned with World Health Assembly resolution WHA75.8 (2022) on strengthening clinical trials. The plan outlines nine priority actions to support countries and stakeholders reform and sustain clinical trial systems that are fit for purpose, inclusive and locally led.

    Anchored in WHO’s 2024 Guidance for best practices for clinical trials, GAP-CTS addresses persistent disparities in trial activity and access, especially in low- and middle-income countries, and calls for systemic improvements to trial funding, design, coordination and ethical oversight.

    The nine actions are designed to:

    • strengthen national leadership and governance of research systems
    • enhance engagement with patients, communities and the public
    • address barriers faced by under-represented populations
    • adopt innovative designs and digital technologies
    • accelerate access to training for the research workforce
    • improve regulatory and ethics review efficiency
    • integrate trials into health systems and routine care
    • improve research transparency via trial registries
    • expand international collaboration across regions and sectors.

    “Reformed research and clinical trial ecosystems will lead to more equitable access to research capacity, better trained workforces and higher quality evidence that meets local population needs,” said Dr Jeremy Farrar, Chief Scientist at WHO.

    To support uptake, WHO will convene partners through the Global Clinical Trials Forum (GCTF) – a WHO-managed network that facilitates peer support and knowledge exchange on implementing these actions. All stakeholders– including WHO Member States, funders, regulators, trial sponsors, patient and community engagement organizations, and research institutions – are called to align their efforts with GAP-CTS, contribute data to monitor progress and support collaborative reforms.

    The GAP-CTS is designed to be used by a wide range of stakeholders, including those involved in trial funding prioritization, ethics oversight, patient and community involvement, regulation and clinical research delivery, with the goal of creating sustainable and resilient ecosystems for high-quality clinical research.

    Read the full action plan: Global action plan for clinical trial ecosystem strengthening

    For questions or engagement opportunities: wha758@who.int

    MIL OSI United Nations News –

  • MIL-OSI USA: Warren, Wyden, Doggett, Schakowsky Push Congressional Leadership to Reject Medicaid Cuts, Crack Down on Medicare Advantage Upcoding

    US Senate News:

    Source: United States Senator for Massachusetts – Elizabeth Warren
    May 08, 2025
     Congressional Republicans’ current plan sets them up to slash hundreds of billions from Medicaid and CHIP
    Lawmakers cite bipartisan support for cracking down on waste, fraud, and abuse in Medicare Advantage
    Letter from House (PDF) | Letter from Senate (PDF)
    Washington, D.C. – As Congress considers reconciliation legislation, Senator Elizabeth Warren (D-Mass.), Senator Ron Wyden (D-Ore.), Ranking Member of the Senate Finance Committee, along with Representatives Lloyd Doggett (D-Texas) and Jan Schakowsky (D-Ill.) led their colleagues in writing to Senate Majority Leader John Thune and Speaker of the House Mike Johnson, urging them to crack down on waste, fraud, and abuse in Medicare Advantage (MA) instead of forging ahead with cuts to Medicaid.
    “As Congress considers reconciliation legislation, we urge you to reject cuts to Medicaid, which are deeply unpopular and will rip away health care from millions of Americans,” wrote the lawmakers. “Where there is widespread agreement is the need to address waste, fraud, and abuse by private, for-profit insurance companies. We write to urge you to crack down on the growing threat to the Medicare program known as ‘upcoding.’”
    Upcoding is the practice by which private insurers in Medicare Advantage exaggerate the medical diagnoses of their enrollees to secure higher payments from the federal government. This results in wasteful spending in Medicare, overcharging seniors and taxpayers while adding tens of billions in costs to the federal government. Analysis from the non-partisan Medicare Payment Advisory Committee (MedPAC) found that upcoding is expected to increase Medicare payments to private health insurance companies by an estimated 10 percent, or $40 billion, in 2025.
    This waste, fraud, and abuse has been called out by both Democrats and Republicans. CMS Administrator Mehmet Oz even noted that tackling this fraud “is relatively enjoyable to go after, because … we have bipartisan support.” Senator Chuck Grassley (R-IA) has launched an inquiry into UnitedHealth’s billing practices in Medicare Advantage, and Senator Bill Cassidy (R-LA) supports the No UPCODE Act, which would ban some of the most aggressive forms of upcoding by private insurers in the program.
    “The Wall Street Journal, MedPAC, Administrator Oz, and Congressional Republicans all seem to agree: wasteful spending in MA, driven by abusive upcoding practices, are a ‘more rational’  route to securing health care savings that will benefit the Medicare program and taxpayers,” continued the lawmakers. “Your directive to cut federal health care spending should come from reducing waste, fraud, and abuse like upcoding by for-profit insurance companies, not by cutting health care benefits for American families who rely on Medicaid to make ends meet.”
    Nevertheless, Congressional Republicans are forging ahead with plans to slash hundreds of billions of dollars from Medicaid and the Children’s Health Insurance Program (CHIP)  – which will put health and livelihoods at risk for the nearly 80 million Americans, including 37 million children, eight million people with disabilities, and seven million seniors covered by these programs
    “If there is no course correction that protects Medicaid, tens of millions of Americans will be kicked off their health care,” wrote the lawmakers. “We urge you instead to listen to Administrator Oz and tackle real fraud, waste, and abuse by private, for-profit health insurers in MA.”
    The letters were also signed by Senators Bernie Sanders (D-Vt.), Tina Smith (D-Minn.), and Senator Jeff Merkley (D-Ore.), as well as Representatives Hank Johnson (D-Ga.), Mark Pocan (D-Wis.), Adam Smith (D-Wash.), Ayanna Pressley (D-Mass.), Joaquin Castro (D-Texas), Rashida Tlaib (D-Mich.), Summer Lee (D-Pa.), Nydia Velazquez (D-N.Y.), Betty McCollum (D-Minn.), Al Green (D-Texas), John Garamendi (D-Calif.), Lateefah Simon (D-Calif.), Alexandria Ocasio-Cortez (D-N.Y.), Eleanor Homes Norton (D-D.C.), Raja Krishnamoorthi (D-Ill.), Pramila Jayapal (D-Wash.), Delia Ramirez (D-Ill.), Ilhan Omar (D-Minn.), Mark Takano (D-Calif.), Danny Davis (D-Ill.), Steve Cohen (D-Tenn.), Maxwell Frost (D-Florida), Chuy Garcia (D-Ill.), Sylvia Garcia (D-Texas), Greg Casar (D-Texas), Bonnie Watson Coleman (D-N.J.), Chris Deluzio (D-Pa.), Jill Tokuda (D-Hawaii), Val Hoyle (D-Ore.), Shri Thanedar (D-Mich.), Andre Carson (D-Ind.), Adriano Espaillat (D-N.Y.), Marcy Kaptur (D-Ohio), and Melanie Stansbury (D-N.M.).
    The letters have been endorsed by the Center for American Progress, Center for Medicare Advocacy, LeadingAge, P Street Project, Protect Our Care, and Public Citizen. 

    MIL OSI USA News –

  • MIL-OSI USA: Wyden, Duckworth, Murray and Booker Lead Colleagues in Demanding Answers About Firings of Congressionally-Mandated CDC IVF Team

    US Senate News:

    Source: United States Senator Ron Wyden (D-Ore)
    May 08, 2025
    “The Trump administration is now moving beyond broken promises to purposely dismantling the very system that provides hopeful families with accountability and transparency regarding fertility clinic success rates.”
    Washington, D.C. — U.S. Senators Ron Wyden, D-Ore., Tammy Duckworth, D-Ill., Patty Murray, D-Wash., and Cory Booker, D-N.J., today led colleagues in demanding answers from Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. for eliminating the Centers for Disease Control and Prevention (CDC) team responsible for making sure people who are trying to become pregnant have the information they need to thoughtfully and safely grow their families – despite Donald Trump’s broken promise to support families seeking IVF treatments.
    “Because IVF is a complicated and expensive process, the American people deserve access to the best information possible to inform their family building journey. Unfortunately, hollowing out National Assisted Reproductive Technology (ART) Surveillance System capabilities and capacity is consistent with Donald Trump’s deceitful and disingenuous rhetoric on IVF,”  the senators wrote in a letter to HHS Secretary Kennedy. “Your actions threaten hopeful parents and families’ ability to access high-quality, safe, and effective fertility care. The American people deserve assurances that their rights under the [Fertility Clinic Success Rate and Certification Act of 1992] will continue to be guaranteed, as Congress intended.”
    The Assisted Reproductive Technology Surveillance and Research team (ARTS) was established following a 1992 Wyden law passed by Congress aimed at guaranteeing consumer protections for people seeking to grow their family through IVF and other assisted reproductive technology. The fired team of six deeply qualified scientists and public health practitioners were responsible for carrying out the CDC’s mandated responsibilities under the Wyden law, including conducting IVF clinic data analysis related to success rates and important clinic oversight through yearly audits and site visits and the monitoring of lab certification status.
    ARTS served as a critical source of unbiased information for patients seeking fertility treatment, collecting and maintaining data on approximately 98 percent of all IVF and assisted reproductive technology cycles performed in the United States.
    In addition to Wyden, Duckworth, Murray, and Booker, the letter was signed by Richard Blumenthal, D-Conn., Kirsten Gillibrand, D-N.Y., John Hickenlooper, D-Colo., Mazie Hirono, D-Hawai’i, Amy Klobuchar, D-Minn., Jon Ossoff, D-Ga., Charles Schumer, D-N.Y., Raphael Warnock, D-Ga., and Elizabeth Warren, D-Mass. 
    The senators demanded the immediate rehiring of every civil servant formerly on the ARTS team and answers to the following questions by Friday, May 16:

    When will you reinstate the entirety of the ARTS team?

    How many employees on the ARTS team, and any supporting contracts, have been fired since January 20, 2025? Please provide a complete breakdown by position, provide information on GS level and veteran status, and clearly state the justification for termination. This accounting should include any employees who have since been reinstated or placed on administrative leave, noting that change in status.

    Which officials at HHS were involved in these staffing reduction decisions and what planning, if any, was undertaken prior to these reductions? Please describe the events that unfolded and name each office that was involved in the decision. Further, please name the official(s) who approved the staffing reductions as well as specifically indicate if any of the below individuals, or direct reports to these individuals, were involved in the decision-making. Name any such direct reports. 

    Elon Musk, Special Government Employee, DOGE.

    Amy Gleason, Acting Administrator, DOGE.

    Susan Monarez, Acting Director, First Assistant to the Director, Principal Deputy Director, CDC.

    Without an ARTS team, how will the CDC continue to carry-out its statutorily-required responsibilities under FCSRCA? Please provide a detailed plan, including noting who has the expertise, skills, capacity, and resources to carry-out the responsibilities formerly carried-out by the ARTS team. 

    Have, or will, any of the CDC’s responsibilities previously carried-out by the ARTS team been contracted out? 

    If so, what assurance will you give the American people that the data and analysis produced will be comprehensive, transparent, publicly-accessible and cover all IVF cycles annually, as the ARTS team did?

    If so, please describe the cost of contracting out these services. 

    In some instances, the HHS’s Reduction In Force (RIF) efforts have been characterized as final. Those same people have stated that, as per the nature of the layoffs, the roles and responsibilities previously carried out by fired staff cannot be refilled. Is this characterization of the RIF efforts correct?

    If so, how can the CDC continue to carry-out its statutorily required responsibilities under FCSRCA?

    What communication, if any, has been given to IVF clinics in connection with the ARTS layoffs and how to report data going forward? If any such communication was distributed, please produce it.

    Does the CDC continue to collect data from IVF clinics across the country? If so, who is responsible for collecting that data and where is the data presently being stored?

    People considering and undergoing IVF and other assisted reproductive technologies rely on up-to-date information to make informed medical decisions. Each year, CDC collects data from IVF clinics across the country and standardizes this information into a public-facing website and report. 

    As of the ARTS team’s firings, the 2023 data had been fully collected. What is the anticipated release date for the 2023 IVF report? Has this timeline been impacted by the ARTS layoffs?

    Have any of the information categories published in previous years been removed or altered? If so, please describe the changes that have been made to information categories and provide a rationale for any changes.

    The ARTS team was operational for over 30 years and the historical information it held related to ARTS is uniquely instructive to public health efforts and contains sensitive PII about hopeful parents undergoing IVF and their children. How will the CDC maintain patient confidentiality, protect PII, and sustain this critical database moving forward? Please provide a detailed plan.

    Further, who is presently in charge of the historical information previously held by the ARTS Team and where is this information held?

    Was the decision to dismiss the ARTS team made in consultation with any non-governmental entities, including nonprofits, think tanks, advocacy organizations, research or educational institutions, or public policy research organizations.

    If so, please provide any written documents or correspondence that informed this decision and name all non-governmental entities involved in the decision to terminate the ARTS team.

    The full letter text is here. 

    MIL OSI USA News –

  • MIL-OSI: SECU Foundation Awards Grace Clinic of Yadkin Valley with $600,000 Grant for New Medical Facility

    Source: GlobeNewswire (MIL-OSI)

    ELKIN, N.C., May 08, 2025 (GLOBE NEWSWIRE) — SECU Foundation has announced a $600,000 challenge grant for Grace Clinic of Yadkin Valley (GCYV) to assist with the construction of a new medical facility in Elkin, North Carolina. The 7,125 square-foot clinic will allow the non-profit to greatly expand services in its four-county region and increase capacity to serve over 600 patients annually.

    GCYV is a Free and Charitable Clinic (FCC) that provides quality integrated primary healthcare for marginalized individuals, including those with chronic conditions and behavioral health needs. One of eight FCCs in North Carolina serving Medicare and Medicaid patients, GCYV provides access to a region where 18.5% of adults are uninsured and 22.5% of adults are living under the poverty level according to the Robert Wood Johnson Foundation.

    “We are so pleased to support the important work of Grace Clinic of Yadkin Valley,” said SECU Foundation Board member Michael Clements. “GCYV is such a valuable part of the community, providing critical services for the people of this area for almost 20 years. SECU Foundation is thrilled to help fund the construction of a new facility that will expand much-needed services and allow for hundreds more patients to be served each year.”

    “Grace Clinic of Yadkin Valley is extremely grateful to the SECU Foundation for their generous support of the construction of a new Health Center,” said GCYV Executive Director Betty W. Taylor. “The Center will offer a wide range of primary care, behavioral health, medication assistance, and dental services. The new facility will not only expand our services, but also will provide better utilization of space and improved access and parking for handicapped patients.”

    About SECU and SECU Foundation
    A not-for-profit financial cooperative owned by its members, and federally insured by the National Credit Union Administration (NCUA), SECU has been providing employees of the state of North Carolina and their families with consumer financial services for 87 years. SECU is the second largest credit union in the United States with $53 billion in assets. It serves more than 2.8 million members through 275 branch offices, 1,100 ATMs, Member Services Support via phone, www.ncsecu.org, and the SECU Mobile App. The SECU Foundation, a 501(c)(3) charitable organization funded by the contributions of SECU members, promotes local community development in North Carolina primarily through high-impact projects in the areas of housing, education, healthcare, and human services. Since 2004, SECU Foundation has made a collective financial commitment of over $300 million for initiatives to benefit North Carolinians statewide.

    Contact: Jama Campbell, Executive Director, secufoundation@ncsecu.org

    Receiving the check are GCYV Board members and Executive Director Betty W. Taylor (third from the left) surrounded by GCYV and SECU Foundation representatives.

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3386f1c8-bca5-4c86-a42f-b26d83dad106

    The MIL Network –

  • MIL-OSI United Kingdom: Portadown food business fined over food safety breaches

    Source: Northern Ireland City of Armagh

    A Portadown food business has been fined for a number of serious food safety breaches discovered by officers from Armagh City, Banbridge & Craigavon (ABC) Borough Council.

    DFWZ Ltd, operating under the trading name ‘Sals Halal’ which is a retailer at Bridge Street in Portadown, was fined £6,750 for six offences plus additional court fees, when the case came before Craigavon Magistrates Court on Tuesday 6 May.

    The offences included; failure to maintain the food premises in a clean condition; failure to protect against contamination and pest control; placing unsafe food on the market; failure to provide adequate storage and disposal for food waste and refuse, and failure to maintain refuse areas free from animals and pests; failure to implement and maintain food safety procedures; failure to label food products to ensure traceability.

    The case was brought by ABC Council after their Environmental Health officers carried out inspections at the business in May 2024. During inspections, officers found a dead mouse, cleaning deficiencies, expired food products and number of other issues. Formal notices were served by the council but due to the serious nature of the offences, legal proceedings were taken against the company.

    A spokesperson for ABC Council, said: “We welcome the outcome of this prosecution, and the fines imposed demonstrate the seriousness of the breaches identified and the continued failure of the business to comply with food safety and hygiene requirements.”

    They added: “We work with hundreds of businesses across the ABC Borough to ensure that food safety is paramount and thankfully the vast majority of business are very responsible, but where we find failings in food safety, we will take robust action to protect the public. It is important that businesses work with us to maintain these important food safety standards and take the appropriate action when formal notices are served.”

    If you would like to find out more about food safety, you can visit the ABC Council webpage – www.armaghbanbridgecraigavon.gov.uk/business/food-safety/ – which offers helpful advice and guidance on food safety, food business registration and approval, the food hygiene rating scheme and food allergens.

    MIL OSI United Kingdom –

  • MIL-OSI: Xsolis’ Dragonfly Wins “Clinical Efficiency Innovation Award” in 2025 MedTech Breakthrough Awards Program

    Source: GlobeNewswire (MIL-OSI)

    FRANKLIN, Tenn., May 08, 2025 (GLOBE NEWSWIRE) — Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers, today announced that it has been selected as winner of the “Clinical Efficiency Innovation Award” in the 9th annual MedTech Breakthrough Awards program for their Dragonfly product. The MedTech Breakthrough Awards is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market.

    Xsolis’ AI-driven SaaS platform uses real-time predictive analytics to continuously assign an objective medical necessity score and assess the anticipated level of care for every patient. The next generation of the company’s platform was launched in late 2024 as Dragonfly. The enhanced solution enables the use of predictive AI to support nurses and caregivers by removing redundant tasks, enables interoperability and data sharing between other native systems, and provides AI-driven length of stay management.  

    “Xsolis is committed to streamlining the healthcare industry’s friction points – reducing unnecessary and crippling administrative waste to create a sustainable industry,” said Joan Butters, co-founder and CEO of Xsolis. “We developed Dragonfly to empower health systems and health plans to align on medical necessity and care transition decisions earlier in the process so they can take productivity and collaboration to the next level.” Butters added, “The introduction of generative AI, alongside our industry-leading predictive AI, will enable Dragonfly users to further improve efficiency, increase accuracy, and drive better patient outcomes. We thank MedTech Breakthrough for this prestigious recognition among our peers.”

    The MedTech Breakthrough Awards program celebrates excellence and innovation in the health and medical technology industry, recognizing the companies, products, and solutions driving meaningful progress and improving patient care. Spanning a wide range of categories — including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data & Privacy, and beyond — the awards highlight the groundbreaking work that is transforming the healthcare landscape.

    This year’s program saw a record-breaking number of nominations from leading companies and startups across more than 18 countries, showcasing the global impact and momentum of the digital healthcare industry today.

    “Dragonfly meets the evolving needs of health systems and health plans, improving patient care management. Almost a trillion dollars are spent annually on administrative costs in U.S. healthcare, with the greatest area of stress and complexity being payer challenges, according to a 2024 survey of revenue cycle leaders from the Healthcare Financial Management Association,” said Steve Johansson, managing director, MedTech Breakthrough. “Xsolis’ shared application of objective data and predictive analytics has the potential to transform unnecessary payer-provider friction and administrative work. Xsolis has been uniquely solving both of these issues with Dragonfly’s comprehensive data and insights, allowing for more clinician focus, transparency and collaboration between stakeholders, prioritizing patient care.”

    About Xsolis 
    Xsolis is an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers. Dragonfly®, its AI-driven proprietary platform, is the first and only solution to use real-time predictive analytics to continuously assign an objective medical necessity score and assess the anticipated level of care for every patient, enabling more efficiency across the healthcare system. Xsolis is headquartered in Franklin, Tennessee. For more information, visit www.xsolis.com.

    About MedTech Breakthrough
    Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com. 

    Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d436f323-68e5-48ad-b77b-c719051894ed

    The MIL Network –

  • MIL-OSI: RTI Connext® Named “Best Overall Connected Healthcare Solution” by MedTech Breakthrough Awards Program

    Source: GlobeNewswire (MIL-OSI)

    SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Real-Time Innovations (RTI), the software framework company for physical AI systems, today announced that RTI Connext® has been selected as the winner of the “Healthcare Overall Best Connected Healthcare Solution” award conducted by MedTech Breakthrough. This marks RTI’s second win in the program, underscoring its leadership in providing AI-enabled connectivity solutions to leading MedTech companies across surgical robotics, patient monitoring, critical care, and medical imaging. Connext provides a real-time, data-centric software framework that accelerates the development of interoperable, intelligent, and secure medical systems.

    “We’re honored to receive this award that recognizes our contributions in enabling the next wave of innovation in medical technology,” said Stan Schneider, CEO of RTI. “With Connext, development teams can focus on building intelligent architectures without worrying about managing complex infrastructure. As a trusted partner to many industry leaders, RTI is proud to provide the foundational software that enables the future of connected, AI-powered healthcare.”

    As organizations increasingly shift toward AI-driven capabilities, RTI delivers the foundational software infrastructure to support this transformation. Most recently, RTI introduced Connext® AI, a suite of LLM-powered tools designed to build robust, scalable real-time systems. By offering intelligent assistance with system design, coding, and debugging, Connext AI accelerates time to market, streamlines development workflows, and enhances overall system reliability.

    Notably, Connext plays a pivotal role in enabling NVIDIA Holoscan to integrate AI into existing healthcare systems—bridging legacy infrastructure with the future of intelligent care. Connext is also a foundational component in advanced surgical robotics, supporting more than 15 commercial programs that integrate diverse surgical elements. This versatility is exemplified in applications ranging from remote surgery—such as Monogram Orthopaedics’ world-first fully remote total knee arthroplasty—to powering minimally invasive platforms like Levita Magnetics’ MARS system.

    “The healthcare industry requires smart, connected devices to process high-speed data and leverage interoperable applications and systems across components, platforms, and networks,” said Steve Johansson, Managing Director, MedTech Breakthrough. “RTI’s technology delivers on this need, providing a data-centric framework where distributed applications can seamlessly access data flowing anywhere in the system. We extend our sincere congratulations to the entire RTI team for taking home our ‘Healthcare Overall Best Connected Healthcare Solution’ award.”

    To learn more about RTI in MedTech, please visit the RTI website: rti.com/healthcare.

    About RTI

    RTI is the software framework company for physical AI systems, with a mission to run a smarter world. RTI Connext® provides the data architecture for over 2,000 designs in Aerospace and Defense, Medtech, Automotive, and Robotics – running in more than $1T of total deployed systems worldwide. Only RTI combines decades of technical expertise with industry-leading software and tools to develop smarter systems, faster. Learn more at www.rti.com.

    Media Contacts:

    Tiffany Yang
    Public Relations, RTI

    The MIL Network –

  • MIL-OSI USA: Lab-synthesized botanical compound shows promise for fighting aggressive breast cancer

    Source: US Government research organizations

    Chemists created a new process for synthesizing complex natural compounds that can also boost their efficacy and therapeutic potential

    Chemists funded by the U.S. National Science Foundation have developed a new process to synthesize a plant-based compound that shows effectiveness against triple-negative breast cancer cells. According to the American Cancer Society, triple-negative breast cancer is one of the most aggressive types of breast cancer and accounts for 10-15% of all breast cancer cases. The process also increases the compound’s potency against these cancer cells and provides a method for it to be mass-produced to enable further testing as a potential treatment.

    The new process can also be used broadly to help discover new medicines by synthesizing and testing other complex organic compounds. The findings were achieved by Emory University researchers and published in The Journal of the American Chemical Society.

    The compound — called phaeocaulisin A — is extracted from the flowering plant Curcuma phaeocaulis, a relative of ginger and turmeric used for centuries in traditional medicine.

    “We not only efficiently replicated a complex natural product, we also improved upon it by turning it into a more potent compound,” says Mingji Dai, professor of chemistry and co-lead of the study.

    “It is only the first step in a long process,” says Yong Wan, professor of pharmacology and chemical biology and study co-lead. “But the new analogue of phaeocaulisin A we have reported shows promising efficacy against triple-negative breast cancer cells, which are very aggressive and challenging to deal with.”

    The study describes how the unique molecular structure of phaeocaulisin A works against triple-negative breast cancer by inhibiting it as a particularly effective anti-inflammatory agent. Wan and Dai were drawn to understand this property and improve upon it with their lab-synthesized analogue version.

    Credit: Sarah Woods, Emory University

    Mingji Dai (right), professor of chemistry at Emory University, and Yong Wan (left), professor of pharmacology and chemical biology at Emory School of Medicine, invented a reaction to streamline the total synthesis of a compound, phaeocaulisin A, extracted from a plant used for centuries in traditional medicine.

    Other chemists have synthesized phaeocausilin A before by using a 17-step method. But Wan and Dai wanted to find a more efficient way. In the process, they devised a new type of chemical reaction to create complex molecules: palladium-catalyzed carbonylation, which uses low-cost and widely available carbon monoxide as a resource. This discovery also cuts down their total synthesis of phaeocausilin A from 17 to 10 steps.

    “The icing on the cake,” says Dai, “is that the chemical reaction we invented holds potential for widespread use in organic chemistry to make many other compounds for drug discovery.”

    “What is so exciting to me about this work is that this methodology can be broadly applied to other synthetic targets. These reactions enable chemists to rethink strategies for how to piece together molecules, like building a Lego set with a different, shorter, set of instructions,” says John Jewett, program director in the NSF Division of Chemistry, which supported the research.

    The chemists say the compound and this method will require years of further research to evaluate its full potential. That said, it’s already shown possibilities for production at scale, and in preparation for commercial therapeutic use.

    “My lab’s focus is to find ways to integrate basic research into translational research,” Wan says. “We are not only trying to understand the mystery of mechanisms behind cancer. We also want to bring strategies to neutralize cancer to the clinical bedside.”

    MIL OSI USA News –

  • MIL-OSI Security: Nurse Admits Tampering With Vials Of Fentanyl

    Source: Office of United States Attorneys

    DETROIT – A Grosse Pointe Park registered nurse, Travis Eskridge, pleaded guilty to tampering with a consumer product, specifically the Schedule II controlled substance fentanyl.  The announcement was made by United States Attorney Jerome F. Gorgon Jr.

    Gorgon  was joined in the announcement by Special Agent in Charge Ronne Malham, FDA Office of Criminal Investigations Chicago Field Office.

    Travis Eskridge, 53, of Grosse Pointe Park, Michigan, worked as a registered nurse in the emergency room at Ascension St. John Hospital.  In his guilty plea Eskridge admitted that he tampered with vials containing fentanyl, a powerful narcotic pain reliever, which he knew were intended to be administered to patients in the hospital’s emergency room. Eskridge removed fentanyl from the vials, replaced fentanyl with another liquid, and returned the tampered vials to the locked drug storage system. Eskridge did this with reckless disregard for the dangerous risk to patients that resulted from such tampering.  The defendant also admitted that he stole fentanyl vials as part of a pattern of thefts over several months.  Nurse Eskridge was immediately removed from his position at Ascension St. John Hospital in August of 2022 when the hospital discovered the tampering and thefts.     

    United States Attorney Gorgon stated, “Licensed medical professionals are supposed to be healers.  Most are. When instead of healing they create a serious risk of harm to patients, the community must and will be protected.  This Office will prosecute such cases to the fullest extent of the law.”

    “Patients rely on receiving the proper FDA-approved medications from those entrusted with their medical care,” said Special Agent in Charge Ronne Malham, Food and Drug Administration, Office of Criminal Investigations, Chicago Field Office. “We must hold medical personnel accountable when they take advantage of their unique position and tamper with medications their patients need.”

    Travis Eskridge pled guilty before United States District Judge Susan K. DeClercq.  His bond was continued under conditions that included not seeking employment as a nurse.  Eskridge is scheduled to be sentenced on September 11, 2025.

    The maximum penalties provided by statute for this offense include up to 10 years of imprisonment, a maximum fine of $250,000, and supervised release of up to 5 years.  The actual sentence imposed upon any conviction would be decided by the Court, after consideration of the United States Sentencing Guidelines.

    The case is investigated by special agents of the Food and Drug Administration. 

    MIL Security OSI –

  • MIL-OSI Global: When doctors don’t believe their patients’ pain – experts explain the all-too-common experience of medical gaslighting

    Source: The Conversation – USA – By Elizabeth Hintz, Assistant Professor of Health Communication, University of Connecticut

    Medical gaslighting stems from centuries of gender bias in medicine. SimpleImages/Moment via Getty Images

    For people with chronic gynecological pain conditions, pain can be constant, making everyday activities like sitting, riding a bicycle and even wearing underwear extremely uncomfortable. For many of these people – most of whom identify as women – sexual intercourse and routine pelvic exams are unbearable.

    Endometriosis and vulvodynia, or chronic genital pain, are common gynecological conditions that can cause severe pain. They each affect about 1 in 10 American women.

    Yet many women face skepticism and gaslighting in health care settings when they seek care for this type of pain.

    We know this well through our research on social cognition and on how people with misunderstood health conditions manage difficult conversations with their doctors and family, as well as through volunteer work alongside people living with these conditions.

    We’ve consistently found that medical gaslighting around chronic gynecological pain is a complex societal problem, fueled by holes in medical research and training.

    ‘It’s all in your head’

    A 2024 study of patients who went to a clinic for vulvovaginal pain – pain experienced in the external female genitals and vagina – found that 45% of these patients had been told that they “just needed to relax more” and 39% were made to feel that they were “crazy”. A staggering 55% had considered giving up on seeking care.

    These results echo what one of us – Elizabeth Hintz – found in her 2023 meta-synthesis: Female patients with chronic pain conditions frequently hear this “It’s all in your head” response from doctors.

    Another study followed patients in two different major U.S. cities who were seeking care for vulvovaginal pain. The researchers found that most patients saw multiple clinicians but never received a diagnosis. Given the challenges of seeking medical care, many patients turn to social media sources like Reddit for support and information.

    These studies, among others, illustrate how people with these conditions often spend years going to clinician after clinician seeking care and being told their pain is psychological or perhaps not even real. Given these experiences, why do patients keep seeking care?

    “Let me describe the pain that would drive me to try so many different doctors, tests and treatments,” a patient with vulvovaginal pain said to her doctor. For her, sex “is like taking your most sensitive area and trying to rip it apart.”

    “I can now wear any pants or underwear that I want with no pain,” said another patient after successful treatment. “I never realized how much of a toll the pain took on my body every day until it was gone.”

    The World Health Organization estimates that at least 1 in 10 women suffers from endometriosis, yet many doctors miss it or dismiss it.

    Medical gaslighting

    Many patients worldwide experience medical gaslighting – a social phenomenon where a patient’s health concerns are not given appropriate medical evaluation and are instead downplayed, misattributed or dismissed outright.

    Medical gaslighting is rooted in centuries of gender bias in medicine.

    Women’s reproductive health issues have long been dismissed as psychological or “hysterical.” Genital and pelvic pain especially has been misattributed to psychological rather than biological causes: A century ago, Freudian psychoanalysts incorrectly believed that female sexual pain came from psychological complexes like penis envy.

    These historical views help shed light on why these symptoms are still not taken seriously today.

    Consequences of medical gaslighting

    In addition to the physical toll of untreated pain, medical gaslighting can take a psychological toll. Women may become isolated when other people do not believe their pain. Some internalize this disbelief and can begin to doubt their own perceptions of pain and even their sanity.

    This cycle of gaslighting compounds the burden of the pain and might lead to long-term psychological effects like anxiety, depression and post-traumatic stress symptoms. For some, the repeated experience of being dismissed by clinicians erodes their sense of trust in the health care system. They might hesitate to seek medical attention in the future, fearing they will once again be dismissed.

    Although some chronic gynecological pain conditions like endometriosis are gaining public attention and becoming better understood, these dynamics persist.

    A funding crisis

    Part of the reason for the misunderstanding surrounding chronic gynecological pain conditions is the lack of research on them. A January 2025 report from the National Academies found that research on diseases disproportionately affecting women were underfunded compared with diseases disproportionately affecting men.

    This problem has gotten worse over time. The proportion of funding from the National Institutes of Health spent on women’s health has actually declined over the past decade. Despite these known disparities, in April 2025 the Trump administration threatened to end funding for the Women’s Health Initiative, a long-running women’s health research program, further worsening the problem.

    Without sustained federal funding for women’s health research, conditions like endometriosis and vulvodynia will remain poorly understood, leaving clinicians in the dark and patients stranded.

    Disparities in care

    As hard as it is for any female patient to have their pain believed and treated, gaining recognition for chronic pain is even harder for those who face discrimination based on class or race.

    One 2016 study found that half of the white medical students surveyed endorsed at least one false belief about biological differences between Black and white patients, such as that Black people have physically thicker skin or less sensitive nerve endings than white people. The medical students and residents who endorsed these false beliefs also underestimated Black patients’ pain and offered them less accurate treatment recommendations.

    Research shows that medical students and residents often hold false beliefs about biological differences between Black and white patients.
    FG Trade Latin/E+ via Getty Images

    Studies show that women are more likely to develop chronic pain conditions and report more frequent and severe pain than men. But women are perceived as more emotional and thus less reliable in describing their pain than men. Consequently, female patients who describe the same symptoms as male patients are judged to be in less pain and are less likely to be offered pain relief, even in emergency settings and with female clinicians. Compared to male patients, female patients are more likely to be prescribed psychological care instead of pain medicine.

    These lingering erroneous beliefs about gender and race are key reasons patients’ pain is dismissed, misunderstood and ignored. The very real-life consequences for patients include delayed diagnosis, treatment and even death.

    Practical steps to disrupt medical gaslighting

    Correcting these problems will require a shift in clinical training, so as to challenge biased views about pain in women and racial minorities and to educate clinicians about common pain conditions like vulvodynia. Research suggests that medical training needs to teach students to better listen to patients’ lived experiences and admit when an answer isn’t known.

    In the meantime, people navigating the health care system can take practical steps when encountering dismissive care.

    They can educate themselves about chronic gynecological pain conditions by reading books like “When Sex Hurts: Understanding and Healing Pelvic Pain” or educational information from trusted sources like the International Society for the Study of Women’s Sexual Health, the International Pelvic Pain Society and the International Society for the Study of Vulvovaginal Disease.

    Although these steps do not address the roots of medical gaslighting, they can empower patients to better understand the medical conditions that could cause their symptoms, helping to counteract the effects of gaslighting.

    If someone you know has experienced medical gaslighting and would like support, there are resources available.

    Organizations like The Endometriosis Association and the National Vulvodynia Association offer support networks and information – like how to find knowledgeable providers. Additionally, connecting with patient advocacy groups like Tight Lipped can provide opportunities for patients to engage in changing the health care system.

    Elizabeth Hintz volunteers with Tight Lipped, a non-profit patient advocacy organization by and for people with chronic vulvovaginal and pelvic pain.

    Marlene Berke volunteers with Tight Lipped, a non-profit patient advocacy organization by and for people with chronic vulvovaginal and pelvic pain.

    – ref. When doctors don’t believe their patients’ pain – experts explain the all-too-common experience of medical gaslighting – https://theconversation.com/when-doctors-dont-believe-their-patients-pain-experts-explain-the-all-too-common-experience-of-medical-gaslighting-250770

    MIL OSI – Global Reports –

  • MIL-OSI Security: Defense News: Navy nurse reflects on rewarding temporary assignment to Guam

    Source: United States Navy

    AGANA HEIGHTS, Guam – Lt. Jodi Carroz, an Emergency Department Registered Nurse stationed at Naval Hospital Twentynine Palms recently returned from a temporary assignment at U.S. Naval Hospital Guam in April, bringing with her a wealth of experience, clinical knowledge, and unforgettable memories.

    MIL Security OSI –

  • MIL-OSI United Kingdom: New nursing team to support end-of-life patients08 May 2025 ​A new team of nurses, who will support Islanders with life-limiting illnesses and their families to live well, will start next month [June]. The Living Well team will help to co-ordinate care for patients… Read more

    Source: Channel Islands – Jersey

    08 May 2025

    ​

    A new team of nurses, who will support Islanders with life-limiting illnesses and their families to live well, will start next month [June].

    The Living Well team will help to co-ordinate care for patients who are in their last 12 months of life – addressing everything from their physical needs to their spiritual, psychological and social wishes. 

    The appointment of the team is the latest milestone to be achieved by the End-of-Life Partnership – a group made up of Health and Care Jersey, Jersey Hospice Care and several organisations across the Island involved in caring for Islanders who are on their end-of-life journey.

    And to celebrate the achievements of the Partnership, as well as to encourage Islanders to talk about death and dying, a pop-up event will be held in town next week [15 May]. 

    The Living Well team, who will be based at Jersey Hospice but will work across the community and in Jersey General Hospital, embodies key elements set out in the Palliative and End-of-Life Care Strategy for Adults in Jersey, including collaboration among health and care providers and a focus on personalised care and individual needs and wishes.

    Rose Naylor, Director of Palliative Care Services at Jersey Hospice Care, said: “This is very much a welcomed development for Islanders especially as we know life can change quickly after a life-limiting diagnosis, and it is normal for people to feel overwhelmed.

    “The Living Well Team of experienced nurses will support Islanders and their families from the point of diagnosis with whatever matters most to them – whether that is managing symptoms, talking through worries, or helping with practical concerns. They will work alongside other health and care providers to support care that is co-ordinated and enables the person to live well in a way that is right for them.” 

    Another success that the group is celebrating is the appointment of a doctor and two nurse educators to provide health and care workers as well as family carers with the skills needed to deliver holistic and compassionate care for dying Islanders. The need for such training was identified in the strategy.

    Under the training, healthcare workers are taught about advance care planning and the importance of having early conversations with patients to learn how they wish to be cared for as their illness progresses. They also learn about symptom control so they can help ease a person’s symptoms such as pain, and nausea, to give a patient, the best quality of life. 

    The new services are funded in partnership between Jersey Hospice Care and HCJ. The funding provided though HCJ was allocated by the States Assembly in a previous Government Plan to enhance palliative and end of life care.

    Organisations involved in the Partnership Group will discuss the services that they offer at a pop-up stand at Charing Cross on Thursday 15 May. Jersey’s celebration event follows on from Dying Matters Week – a national week held between 5 and 11 May which aims to break down the taboo of talking about death and dying.​​

    Dr James Grose, chair of the End of Life Care Partnership Group and doctor undertaking the medical educator role, said: “I’m incredibly proud of the work that has been achieved by the Partnership Group. The establishment of the Living Well team, along with the appointment of the educator roles, shows we have made meaningful strides in being able to provide the best possible end-of-life and palliative care for Islanders. 

    “I hope Islanders take the opportunity to find out more about the Partnership and the work that we have been doing by visiting our pop-up stall this week.”

    ​

    MIL OSI United Kingdom –

  • MIL-OSI: Caliber Receives Design Review Approval for PURE Pickleball & Padel Project

    Source: GlobeNewswire (MIL-OSI)

    SCOTTSDALE, Ariz., May 08, 2025 (GLOBE NEWSWIRE) — Caliber (NASDAQ: CWD), a real estate investor, developer, and manager, today announced that its joint venture development, PURE Pickleball & Padel™ has gained Design Review approval from the Salt River Pima-Maricopa Indian Community (SRPMIC) Planning Department. This approval positions the project to seek a building permit once final construction documents are complete, with a planned ground-breaking shortly after receiving the permit.

    PURE Pickleball & Padel™ is developing an 11+ acre site in the Riverwalk Development Project located in the Talking Stick Entertainment District, a 100-acre site in the SRPMIC adjacent to Scottsdale. PURE will be a world-class pickleball and padel facility and seeks to claim the title of the largest indoor pickleball and padel facility in the world. The 196,726 square feet state-of-the-art facility will boast a 1,200-seat pro arena, 48 indoor courts (40 pickleball, 8 padel), sports performance and recovery fitness center by HonorHealth, restaurant and rooftop bar, pro shop, locker rooms and spa, special event spaces, childcare and other amenities.

    Chris Loeffler, CEO of Caliber, said, “We are grateful to the SRPMIC team for their thoughtful review and approval of this project. Collaboration with the SRPMIC has been instrumental throughout the design review process which has brought an elevated design and uniqueness to the project.”

    Kevin J. Berk, Co-Founder & CEO of PURE, said, “I want to extend my heartfelt thanks to the SRPMIC for believing in and supporting our vision. I’m deeply grateful to all the incredible teams contributing to this project—your passion, dedication, and commitment to bringing our first facility to life inspires me every day.”

    With the approval of the use and design, the PURE project will now focus on the next phase of development, the completion of construction documents and the approval of a final building permit. This approval also positions Caliber to formally enter the debt markets to finalize its sourcing of construction financing and puts a clear timeline in place for investors funding the equity into the project’s private offering.

    Unique to this project, Caliber created the [insert official fundco offering name here], a single asset offering designed to invest in the real estate, land sublease, and business operations of PURE. The offering allows for direct investment from accredited investors as well as qualified opportunity zone funds (QOFs) seeking to allocate capital to a potentially attractive qualified opportunity zone business (QOZB). Caliber has designed the offering for broad participation, seeking Pickleball & Padel enthusiasts who are looking for exposure to the two fastest growing sports in the United States and the World.

    For more information on the project, visit Caliber’s website.

    About Caliber (CaliberCos Inc.)

    With over $2.9 billion in Managed Assets, Caliber’s 16-year track record of managing and developing real estate is built on a singular goal: to make money in all market conditions, specializing in hospitality, multi-family residential, and multi-tenant industrial. Our growth is fueled by performance and a key competitive advantage: we invest in projects, strategies, and geographies that global real estate institutions often overlook. Integral to this advantage is our in-house shared services group, which gives Caliber greater control over our real estate and enhanced visibility into future investment opportunities. There are multiple ways to participate in Caliber’s success: invest in Nasdaq-listed CaliberCos Inc. and/or invest directly in our Private Funds.

    About PURE Pickleball & Padel
    PURE Pickleball & Padel has partnered with Caliber to build the world’s largest indoor pickleball & Padel facility and pro arena in Scottsdale, Arizona, with a target opening date of late 2026. The 196,726 square feet state-of-the-art facility will boast 48 indoor courts (40 Pickleball and 8 Padel), a 1,200-seat pro arena, along with country club level amenities that include a restaurant and bar, retail pro shop, gym, recovery spaces, VIP lounge, office space, childcare and teen room. PURE is a member-focused, program-driven concept that will connect the two fastest growing sports in the world with the Scottsdale community across all ages, skill levels, and backgrounds. With an estimated 800,000 visits annually, the facility plans to host the largest pickleball/padel tournaments in the world.

    About the Talking Stick Entertainment District
    The Talking Stick Entertainment District is a dynamic area for culture, shopping, dining and entertainment, conveniently located within the Salt River Pima-Maricopa Indian Community. Located at the Pima-101 Freeway and Talking Stick Way, just 20 minutes from Sky Harbor Airport, Talking Stick is home to Talking Stick Resort, Talking Stick Golf Club, Salt River Fields at Talking Stick, The Pavilions at Talking Stick, Arizona Boardwalk at Talking Stick and many more entertainment and hospitality options.

    About the Salt River Pima-Maricopa Indian Community
    The Salt River Pima-Maricopa Indian Community (SRPMIC) is represented by two distinct Native American tribes; the Akimel O’odham (River People), more commonly known as the Pima and the Xalychidom Piipaash (People Who Live Toward the Water) commonly known as the Maricopa; both share the same cultural values but maintain their unique traditions. Today, more than 11,000 individuals are enrolled Salt River tribal members. The SRPMIC is bordered by Tempe, Fountain Hills and Mesa and shares a Scottsdale address. The Community owns and operates several successful enterprises including Salt River Materials Group and Saddleback Communication and hospitality enterprises: Talking Stick Resort, Talking Stick Golf Club and Salt River Fields at Talking Stick, all within the Talking Stick Entertainment District, on the northern part of the Community. The culture and the history of the people is an important story to tell and have been interwoven at many of the destination amenities through interior art, building design and landscape.

    Forward-Looking Statements
    This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the Company’s public offering filed with the SEC and other reports filed with the SEC thereafter. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

    CONTACTS:
    Caliber Investor Relations:
    Ilya Grozovsky
    +1 480-214-1915
    Ilya@CaliberCo.com

    PURE Pickleball & Padel
    Kevin J. Berk – Co-Founder & CEO
    +1 480-861-7474
    Kevin@purepickleball.com

    The MIL Network –

  • MIL-OSI Global: Alberta has long accused Ottawa of trying to destroy its oil industry. That’s a dangerous myth

    Source: The Conversation – Canada – By Ian Urquhart, Professor Emeritus, Political Science, University of Alberta

    “Alberta is a place soaked in self-deception.” Those words began Alberta-based journalist Mark Lisac’s 2004 book aimed at shattering the myths that have unhelpfully animated too much of Alberta’s politics over the past few decades.

    Current and former Alberta politicians are once again embracing and treating separatist grievances seriously. That means it’s time once again to highlight and challenge political misconceptions that have the potential to destroy Canada.

    Oil is the root of one such myth. The misconception? That Ottawa perenially opposes the oil and gas sector and is determined to stop its continued growth. The National Energy Program (1980), the Northern Gateway pipeline project (2016), the Energy East Pipeline (2017) and the proposed greenhouse gas pollution cap allegedly prove Ottawa’s hostility.

    Notably missing from these grievances is the Keystone XL pipeline and the Trans Mountain Expansion Project. Ottawa supported these projects aimed at transporting Alberta oilsands crude to foreign markets. The federal government even purchased the Trans Mountain project from Kinder Morgan in 2018 — not to kill it, but to build it.



    Read more:
    Justin Trudeau’s risky gamble on the Trans Mountain pipeline

    As for Keystone XL, Alberta Premier Jason Kenney thanked Prime Minister Justin Trudeau for supporting the project. This doesn’t fit the separatist narrative, so it’s largely ignored.

    Oilsands booster

    No one should dispute the National Energy Program’s devastating impact on Alberta’s conventional oil and gas sector 40 years ago. But the oilsands, not conventional oil, propelled Canada to its position as the world’s fourth largest oil producer.

    Has Ottawa facilitated or obstructed the spectacular post-1990 growth of oilsands production?

    The record shows that, since the mid-1970s, Ottawa has facilitated and supported the oilsands sector. The federal government helped keep the Syncrude project alive in 1975 when it took a 15 per cent interest in Canada’s second oilsands operation.

    Ironically, Ottawa’s enthusiasm for more, not less, petroleum from the oilsands also appeared in 1980 via the National Energy Program (NEP), the devil in Alberta’s conservative catechism. What most accounts of the NEP don’t mention is that Ottawa offered tax benefits to oilsands companies while stripping them from conventional oil producers.

    Furthermore, the NEP’s “made-in-Canada” pricing effectively guaranteed Syncrude would receive the world price for its production. At $38 per barrel, Syncrude received more than double what conventional producers received. If the NEP was harsh on conventional oil producers, it helped create a golden future for the oil sands.

    In the mid-1990s, Ottawa helped propel the post-1995 oilsands boom. The industry-dominated National Task Force on Oil Sands Strategies sought federal tax concessions to promote oilsands growth. The federal government delivered them in its 1996 budget, despite Prime Minister Jean Chretien’s general concern with cutting the deficit.

    Again, these measures clearly contradict the myth of federal opposition to the oil industry.

    Generous emissions caps

    Ottawa’s policy favouritism towards the oilsands didn’t end there. It has consistently animated the federal government’s treatment of the oilsands in its climate change policies.

    The federal Climate Change Plan for Canada (2002) treated oil and gas leniently. Its measures for large industrial emitters bore a striking resemblance to the climate change policy preferences of the Canadian Association of Petroleum Producers. Suncor and Syncrude, the two leading oilsands producers, estimated these federal proposals would add a pittance, between 20 and 30 cents, to their per barrel production costs.

    Justin Trudeau’s response to Alberta’s 2015 oilsands emissions cap also underlined Ottawa’s favouritism, not hostility, to the dominant player in Canada’s oil patch.

    Rachel Notley’s NDP government set this cap at 100 million tonnes of GHG per year, plus another 10 million tonnes allowed to new upgrading and co-generation facilities. This cap was a whopping 39 million tonnes or 55 per cent higher than what the oilsands emitted in 2014.

    This generous cap contributed to a tremendous increase in oilsands production. Healthy profits became record profits in 2022. Ottawa embraced Alberta’s largesse, incorporating the province’s cap into its post-2015 climate policies.

    Furthermore, Ottawa increased its leniency towards the oilsands by exempting new in-situ (non-mining) oilsands projects in Alberta from the federal Impact Assessment Act. This exemption applies until Alberta’s emissions cap is reached. Canada’s latest National Inventory Report on greenhouse gas emissions reported record oilsands GHG emissions of 89 million tonnes in 2023, still 11 million tonnes shy of the 100 million tonne threshold.

    Weaponizing myths

    Finally, we have today’s proposed national cap on greenhouse gas emissions. Alberta is apoplectic about the cap. But whether or not it’s intentional, Premier Danielle Smith’s outrage feeds into secessionist sentiment by seemingly misrepresenting the cap’s impact on oil and gas production.

    Smith and her environment minister use the work of the Parliamentary Budgetary Officer (PBO) to nurture their “Ottawa hates oil” narrative. They claim the officer’s analysis of the cap’s economic impact showed it “will cut oil and gas production by five per cent, or more than 245,000 barrels per day.”

    This is simply not true.

    In fact, the PBO concluded that, with the cap, oilsands production “is projected to remain well above current levels” — 15 per cent higher than in 2022. The proposed federal emissions cap, like the Alberta NDP’s cap of a decade ago, is higher than current oilsands emissions levels. The PBO concluded the proposed ceiling for oilsands emissions would be six per cent higher than 2022 emissions.

    Ottawa’s proposed cap, in fact, continues its decades-long support of the oilsands.

    Myths are central to our being. When I tell my grandsons about the pot of gold at the end of the rainbow, I hope to inspire curiosity, imagination and interest in their grandmother’s Irish heritage.

    But in politics, fanciful stories can be dangerous. Some weaponize myths, using the fictions at their core to encourage followers to let falsehoods rule their behaviour. That seems to be playing out yet again in Alberta. We must demand better from the political class.

    Ian Urquhart does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

    – ref. Alberta has long accused Ottawa of trying to destroy its oil industry. That’s a dangerous myth – https://theconversation.com/alberta-has-long-accused-ottawa-of-trying-to-destroy-its-oil-industry-thats-a-dangerous-myth-255908

    MIL OSI – Global Reports –

  • MIL-OSI: Royalty Pharma Reports First Quarter 2025 Results

    Source: GlobeNewswire (MIL-OSI)

    • Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%
    • Net cash provided by operating activities of $596 million
    • Raised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million

    NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts.

    “Our business momentum continued in the first quarter of 2025 as we delivered double-digit growth in Portfolio Receipts and raised our financial guidance,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Guided by our dynamic capital allocation framework, we repurchased over $700 million of our Class A ordinary shares given our attractive outlook, we expanded our development-stage portfolio with an R&D funding partnership with Biogen and we again increased our quarterly dividend. Looking ahead, we have strong fundamental tailwinds underpinning our business with a robust deal pipeline and we remain on track to acquire our external manager in the second quarter. We plan to share further details on our attractive long-term outlook at our upcoming Investor Day in September.”

    Double-digit growth in Royalty Receipts and Portfolio Receipts

    • Royalty Receipts grew 12% to $788 million, primarily driven by strong performance from the cystic fibrosis franchise, Trelegy and Xtandi.
    • Portfolio Receipts increased by 17% to $839 million.

    Significant repurchase activity under recently announced $3 billion authorization

    • Repurchased 23 million Class A ordinary shares for $723 million guided by dynamic capital allocation framework.
    • Capital Deployment of $101 million; entered into Phase 3 R&D funding collaboration for Biogen’s litifilimab.
    • Increased quarterly dividend by approximately 5%.

    Positive clinical and regulatory updates across royalty portfolio

    • Johnson & Johnson’s Tremfya received FDA and EC approval in Crohn’s disease, EC approval in ulcerative colitis.
    • Positive Phase 3 results for Emalex’s ecopipam in Tourette syndrome.
    • Roche to initiate a Phase 3 program for trontinemab in Alzheimer’s disease later this year.

    Raised financial guidance for full year 2025 (excludes contribution from future transactions)

    • Royalty Pharma expects 2025 Portfolio Receipts to be between $2,975 million and $3,125 million, representing expected growth of 6% to 12%.
    • The company expects to update 2025 guidance for payments and operating and professional costs and interest paid after the closing of the internalization transaction, which is expected in the second quarter of 2025.

    Financial & Liquidity Summary

      Three Months Ended March 31,
      (unaudited)
    ($ and shares in millions) 2025 2024 Change
    Portfolio Receipts 839 717 17%
    Net cash provided by operating activities 596 665 (10)%
    Adjusted EBITDA (non-GAAP)* 738 656 12%
    Portfolio Cash Flow (non-GAAP)* 611 584 5%
    Weighted average Class A ordinary shares outstanding – diluted 578 597 (3)%

    *See “Liquidity and Capital Resources” section. Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures calculated in accordance with the credit agreement.

    Portfolio Receipts Highlights

          Three Months Ended March 31,
          (unaudited)
    ($ in millions)     2025 2024 Change
    Products: Marketers: Therapeutic Area:      
    Cystic fibrosis franchise Vertex Rare disease 250 218 14%
    Trelegy GSK Respiratory 85 71 21%
    Tysabri Biogen Neuroscience 61 69 (12)%
    Evrysdi Roche Rare disease 53 45 17%
    Xtandi Pfizer, Astellas Cancer 52 41 28%
    Imbruvica AbbVie, J&J Cancer 46 50 (8)%
    Promacta Novartis Hematology 44 43 4%
    Tremfya Johnson & Johnson Immunology 36 36 (1)%
    Cabometyx/Cometriq Exelixis, Ipsen, Takeda Cancer 21 18 16%
    Spinraza Biogen Rare disease 13 7 95%
    Trodelvy Gilead Cancer 13 10 23%
    Erleada Johnson & Johnson Cancer 11 9 21%
    Other products(5) 105 88 19%
    Royalty Receipts 788 705 12%
    Milestones and other contractual receipts 51 12 309%
    Portfolio Receipts 839 717 17%

    Amounts shown in the table may not add due to rounding.

    Royalty Receipts was $788 million in the first quarter of 2025, an increase of 12% compared to $705 million in the first quarter of 2024. The increase was primarily driven by strong growth from the cystic fibrosis franchise, Trelegy and Xtandi, as well as royalties from the 2024 launch of Voranigo.

    Portfolio Receipts was $839 million in the first quarter of 2025, an increase of 17% compared to $717 million in the first quarter of 2024, primarily driven by the same Royalty Receipts increases noted above and a milestone payment of $27 million related to Airsupra.

    Liquidity and Capital Resources

    Royalty Pharma’s liquidity and capital resources are summarized below:

    As of March 31, 2025, Royalty Pharma had cash and cash equivalents of $1.1 billion and total debt with principal value of $7.8 billion.

    In January 2025, Royalty Pharma completed the sale of the MorphoSys Development Funding Bonds for $511 million in upfront cash. This payment, combined with quarterly repayments received prior to the sale, resulted in total cash proceeds of $530 million on the $300 million investment that was made in September 2022. The proceeds provide added flexibility to pursue the company’s dynamic capital allocation strategy.

    In January 2025, Royalty Pharma announced a new share repurchase program under which it may repurchase up to $3.0 billion of its Class A ordinary shares. During the first quarter of 2025, Royalty Pharma repurchased approximately 23 million Class A ordinary shares for $723 million. During the first quarter of 2024, Royalty Pharma did not repurchase any Class A ordinary shares. The weighted-average number of diluted Class A ordinary shares outstanding for the first quarter of 2025 was 578 million as compared to 597 million for the first quarter of 2024.

    Liquidity Summary

      Three Months Ended March 31,
      (unaudited)
    ($ in millions) 2025   2024  
    Portfolio Receipts 839   717  
    Payments for operating and professional costs (102)   (61)  
    Adjusted EBITDA (non-GAAP) 738   656  
    Interest paid, net (127)   (73)  
    Portfolio Cash Flow (non-GAAP) 611   584  

    Amounts may not add due to rounding.

    • Adjusted EBITDA (non-GAAP) was $738 million in the first quarter of 2025. Adjusted EBITDA is calculated as Portfolio Receipts minus payments for operating and professional costs. Payments for operating and professional costs for the first quarter of 2025 included a $33 million one-time payment related to the management fee on the sale of the MorphoSys Development Funding Bonds.
    • Portfolio Cash Flow (non-GAAP) was $611 million in the first quarter of 2025. Portfolio Cash Flow is calculated as Adjusted EBITDA minus interest paid or received, net. This measure reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases, or utilized for other discretionary investments.

    Refer to Table 4 for Royalty Pharma’s reconciliation of each non-GAAP measure to the most directly comparable GAAP financial measure, net cash provided by operating activities.

    Capital Deployment reflects cash payments during the period for new and previously announced transactions. Capital Deployment was $101 million in the first quarter of 2025, consisting primarily of the upfront research and development (“R&D”) funding for litifilimab (discussed further below) and a milestone payment related to Trelegy.

    In April 2025, Ferring Pharmaceuticals announced U.S. Food and Drug Administration (“FDA”) approval of a new manufacturing hub in Parsippany, NJ for Adstiladrin, its novel gene therapy for bladder cancer. The approval triggered a $200 million milestone payment that was paid in the second quarter of 2025 as part of the royalty agreement announced in 2023.

    The table below details Capital Deployment by category:

    Capital Deployment

      Three Months Ended March 31,
      (unaudited)
    ($ in millions) 2025   2024  
    Acquisitions of financial royalty assets (1)   (86)  
    Development-stage funding payments (51)   (1)  
    Milestone payments (50)   —  
    Investments in equity method investees —   (7)  
    Contributions from legacy non-controlling interests – R&D 0   0  
    Capital Deployment (101)   (93)  

    Amounts may not add due to rounding.

    Royalty Transactions

    In February 2025, Royalty Pharma entered into an R&D funding arrangement with Biogen to provide up to $250 million over six quarters, including $50 million upfront for the development of litifilimab. Litifilimab is in Phase 3 development for the treatment of lupus. The announced transaction amount reflects the entire amount of capital committed for new transactions during the year, including potential future milestones.

    The information in this section should be read together with Royalty Pharma’s reports and documents filed with the SEC at www.sec.gov and the reader is also encouraged to review all other press releases and information available in the Investors section of Royalty Pharma’s website at www.royaltypharma.com.

    Internalization Transaction

    In January 2025, Royalty Pharma agreed to acquire its external manager, RP Management, LLC (the “Manager”) (press release). This transaction to simplify Royalty Pharma’s corporate structure is expected to result in multiple benefits for shareholders. On a financial basis, the acquisition is expected to reduce costs and enhance economic returns on investments. Specifically, the acquisition will generate cash savings of greater than $100 million in 2026, rising to greater than $175 million in 2030 and driving cumulative savings of greater than $1.6 billion over ten years. The acquisition also increases shareholder alignment, enhances corporate governance, ensures management continuity and simplifies Royalty Pharma’s corporate structure.

    The total transaction value of approximately $1.1 billion(7) consists of approximately 24.5 million shares of Royalty Pharma equity that will vest over five to nine years, approximately $100 million in cash(8), and the assumption of $380 million of the Manager’s existing debt.

    The closing of the internalization transaction is subject to shareholders’ approval of the issuance of the share consideration and other customary closing conditions, including required regulatory approvals. The shareholder meeting will take place on May 12, 2025 and the transaction is estimated to close during the second quarter of 2025.

    Key Developments Relating to the Portfolio

    The key developments related to Royalty Pharma’s royalty interests are discussed below based on disclosures from the marketers of the products.

    Tremfya In May 2025, Johnson & Johnson announced that the European Commission (“EC”) approved Tremfya for the treatment of adult patients with moderately to severely active Crohn’s disease.

    In April 2025, Johnson & Johnson announced that the EC approved Tremfya for the treatment of adult patients with moderately to severely active ulcerative colitis.

    In March 2025, Johnson & Johnson announced that the FDA approved Tremfya, which is now the first and only IL-23 offering both subcutaneous and intravenous induction options for the treatment of adults with moderately to severely active Crohn’s disease.
    aficamten In May 2025, Cytokinetics announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application for aficamten to December 26, 2025. The FDA notified Cytokinetics that additional time is required to conduct a full review of the company’s proposed Risk Evaluation and Mitigation Strategy (REMS). No additional clinical data or studies have been requested of Cytokinetics by the FDA.
    Cobenfy In April 2025, Bristol Myers Squibb announced that topline results from the Phase 3 ARISE trial evaluating Cobenfy as an adjunctive treatment to atypical antipsychotics in adults with schizophrenia did not reach the threshold for a statistically significant difference compared to placebo with an atypical antipsychotic for the primary endpoint of the change from baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) total score.
    Trodelvy In April 2025, Gilead announced positive topline results from the Phase 3 Ascent-04/Keynote-D19 study, demonstrating that Trodelvy plus Keytruda significantly improved progression-free survival (“PFS”) compared to Keytruda and chemotherapy in patients with previously untreated PD-L1+ metastatic triple-negative breast cancer. Overall survival (“OS”), a key secondary endpoint, was not mature at the time of the PFS primary analysis. However, there was an early trend in improvement for OS with Trodelvy plus Keytruda. Gilead will continue to monitor OS outcomes, with ongoing patient follow-up and further analyses.
    trontinemab In April 2025, Roche announced that new trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase 1b/2a Brainshuttle AD study. Roche expects to initiate a Phase 3 program for trontinemab later this year.
    ecopipam In February 2025, Emalex announced positive Phase 3 results for ecopipam in patients with Tourette syndrome. The study showed statistical significance between ecopipam and placebo for both the primary efficacy endpoint in pediatrics and the secondary efficacy endpoint in pediatrics and adults. Emalex will meet with the FDA and other global health authorities to discuss submission later this year of a New Drug Application (“NDA”).
    Spinraza In January 2025, Biogen announced that the FDA accepted the supplemental NDA and the European Medicines Agency validated the application for a higher dose regimen of Spinraza for spinal muscular atrophy.
    TEV-‘749 In January 2025, Teva announced that TEV-’749 (olanzapine LAI) achieved Phase 3 targeted injections without PDSS (post-injection delirium/sedation syndrome), and the full safety presentation is expected in the second quarter of 2025.


    2025 Financial Outlook

    Royalty Pharma has provided guidance for full year 2025, excluding new transactions and borrowings announced after the date of this release, as follows:

      Provided May 8th, 2025 Previous
    Portfolio Receipts $2,975 million to $3,125 million
    (Growth of ~+6% to 12% year/year)    		 $2,900 million to $3,050 million
    (Growth of ~+4% to 9% year/year)
    Payments for operating and professional costs Approximately 10% of Portfolio Receipts Approximately 10% of Portfolio Receipts
    Interest paid $260 million $260 million

    The above Portfolio Receipts guidance represents expected growth of 6% to 12% in 2025. Royalty Pharma’s full year 2025 guidance reflects a negligible estimated foreign exchange impact to Portfolio Receipts, assuming current foreign exchange rates prevail for the rest of 2025.

    2025 guidance for payments for operating and professional costs and interest paid does not reflect the impact of the internalization transaction announced on January 10, 2025 and will be updated following the closing of the internalization transaction, which is expected in the second quarter of 2025.

    Total interest paid is based on the semi-annual interest payment schedule of Royalty Pharma’s existing notes and is anticipated to be approximately $260 million in 2025. Interest paid in the third quarter of 2025 is anticipated to be $119 million. De minimis amounts are anticipated in the second and fourth quarter of 2025. These projections assume no additional debt financing in 2025, including no drawdown on the revolving credit facility. In the first quarter of 2025, Royalty Pharma collected interest of $12 million on its cash and cash equivalents, which partially offset interest paid.

    Royalty Pharma today provides this guidance based on its most up-to-date view of its prospects. This guidance assumes no major unforeseen adverse events or changes in foreign exchange rates and excludes the contributions from transactions announced subsequent to the date of this press release.

    Financial Results Call

    Royalty Pharma will host a conference call and simultaneous webcast to discuss its first quarter 2025 results today at 8:30 a.m., Eastern Time. Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days.

    About Royalty Pharma plc

    Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage product candidates.

    Forward-Looking Statements

    The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

    This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities, market growth and plans for capital deployment, plus the benefits of the internalization transaction, including expected accretion, enhanced alignment with shareholders, increased investment returns, expectations regarding management continuity, transparency and governance, and the benefits of simplification to its structure. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
    Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.

    For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at www.sec.gov.

    Portfolio Receipts

    Portfolio Receipts is a key performance metric that represents Royalty Pharma’s ability to generate cash from Royalty Pharma’s portfolio investments, the primary source of capital that is deployed to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. Royalty Receipts includes variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma.

    Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include royalty receipts and milestones and other contractual receipts that were received on an accelerated basis under the terms of the agreement governing the receipt or payment. Portfolio Receipts also does not include proceeds from equity securities or proceeds from purchases and sales of marketable securities, both of which are not central to Royalty Pharma’s fundamental business strategy.

    Portfolio Receipts is calculated as the sum of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees less Distributions to legacy non-controlling interests – Portfolio Receipts, which represent contractual distributions of Royalty Receipts, milestones and other contractual receipts to the Legacy Investors Partnerships.

    Use of Non-GAAP Measures

    Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures that exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. Management believes that Adjusted EBITDA and Portfolio Cash Flow are important non-GAAP measures used to analyze liquidity because they are key components of certain material covenants contained within Royalty Pharma’s credit agreement. Royalty Pharma cautions readers that amounts presented in accordance with the definitions of Adjusted EBITDA and Portfolio Cash Flow may not be the same as similar measures used by other companies or analysts. These non-GAAP liquidity measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of Royalty Pharma’s results as reported under GAAP.

    The definitions of Adjusted EBITDA and Portfolio Cash Flow used by Royalty Pharma are the same as the definitions in the credit agreement. Noncompliance with the interest coverage ratio, leverage ratio and Portfolio Cash Flow ratio covenants under the credit agreement could result in lenders requiring the company to immediately repay all amounts borrowed. If Royalty Pharma cannot satisfy these covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA and Portfolio Cash Flow are critical to the assessment of Royalty Pharma’s liquidity.

    Adjusted EBITDA and Portfolio Cash Flow are used by management as key liquidity measures in the evaluation of the company’s ability to generate cash from operations. Management uses Adjusted EBITDA and Portfolio Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, debt repayments, dividends and other discretionary investments. Further, these non-GAAP liquidity measures help management, the audit committee and investors evaluate the company’s ability to generate liquidity from operating activities.

    The company has provided reconciliations of these non-GAAP liquidity measures to the most directly comparable GAAP financial measure, being net cash provided by operating activities in Table 4.

    Royalty Pharma Investor Relations and Communications

    +1 (212) 883-6772
    ir@royaltypharma.com

     
    Royalty Pharma plc
    Condensed Consolidated Statements of Operations (unaudited)
    Table 1
     
      Three Months Ended March 31,
    ($ in millions) 2025   2024  
    Income and other revenues    
    Income from financial royalty assets 539   542  
    Other royalty income and revenues 29   26  
    Total income and other revenues 568   568  
    Operating (income)/expense    
    Provision for changes in expected cash flows from financial royalty assets (127)   584  
    Research and development funding expense 51   1  
    General and administrative expenses 111   58  
    Total operating expense, net 34   642  
    Operating income/(loss) 534   (74)  
    Other (income)/expense    
    Equity in (earnings)/losses of equity method investees (6)   14  
    Interest expense 65   44  
    Other expense/(income), net 42   (128)  
    Total other expense/(income), net 101   (70)  
    Consolidated net income/(loss) before tax 433   (4)  
    Income tax expense —   —  
    Consolidated net income/(loss) 433   (4)  
    Net income/(loss) attributable to non-controlling interests 195   (9)  
    Net income attributable to Royalty Pharma plc 238   5  

    Amounts may not add due to rounding.

     
    Royalty Pharma plc
    Selected Balance Sheet Data (unaudited)
    Table 2
     
    ($ in millions) As of March 31, 2025 As of December 31, 2024
    Cash and cash equivalents 1,088 929
    Total current and non-current financial royalty assets, net 15,749 15,911
    Total assets 17,608 18,223
    Current portion of long-term debt 999 998
    Long-term debt, net of current portion 6,619 6,615
    Total liabilities 7,820 7,880
    Total shareholders’ equity 9,789 10,342

     

     
    Royalty Pharma plc
    Condensed Consolidated Statements of Cash Flows (unaudited)
    Table 3
     
       
      Three Months Ended March 31,
    ($ in millions) 2025   2024  
    Cash flows from operating activities:    
    Cash collections from financial royalty assets 830   745  
    Cash collections from intangible royalty assets 0   14  
    Other royalty cash collections 32   26  
    Distributions from equity method investees 13   13  
    Interest received 12   6  
    Development-stage funding payments (51)   (1)  
    Payments for operating and professional costs (102)   (61)  
    Interest paid (139)   (79)  
    Net cash provided by operating activities 596   665  
    Cash flows from investing activities:    
    Distributions from equity method investees 36   5  
    Investments in equity method investees —   (7)  
    Purchases of equity securities (4)   —  
    Proceeds from available for sale debt securities 13   1  
    Proceeds from sales of available for sale debt securities 511   —  
    Acquisitions of financial royalty assets (1)   (86)  
    Milestone payments (50)   —  
    Net cash provided by/(used in) investing activities 504   (87)  
    Cash flows from financing activities:    
    Distributions to legacy non-controlling interests – Portfolio Receipts (85)   (88)  
    Distributions to continuing non-controlling interests (54)   (32)  
    Dividends to shareholders (95)   (94)  
    Repurchases of Class A ordinary shares (709)   —  
    Contributions from legacy non-controlling interests – R&D 0   0  
    Contributions from non-controlling interests – other 1   1  
    Net cash used in financing activities (941)   (212)  
    Net change in cash and cash equivalents 159   366  
    Cash and cash equivalents, beginning of period 929   477  
    Cash and cash equivalents, end of period 1,088   843  

    Amounts may not add due to rounding.

     
    Royalty Pharma plc
    GAAP to Non-GAAP Reconciliation (unaudited)
    Table 4
     
      Three Months Ended March 31,
    ($ in millions) 2025   2024  
    Net cash provided by operating activities (GAAP) 596   665  
    Adjustments:    
    Proceeds from available for sale debt securities(6) 13   1  
    Distributions from equity method investees(6) 36   5  
    Interest paid, net(6) 127   73  
    Development-stage funding payments 51   1  
    Distributions to legacy non-controlling interests – Portfolio Receipts(6) (85)   (88)  
    Adjusted EBITDA (non-GAAP) 738   656  
    Interest paid, net(6) (127)   (73)  
    Portfolio Cash Flow (non-GAAP) 611   584  

    Amounts may not add due to rounding.

     
    Royalty Pharma plc
    Description of Approved Indications for Select Portfolio Therapies
    Table 5
     
    Cystic fibrosis franchise Cystic fibrosis
    Trelegy Chronic obstructive pulmonary disease and asthma
    Tysabri Relapsing forms of multiple sclerosis
    Evrysdi Spinal muscular atrophy
    Xtandi Prostate cancer
    Imbruvica Hematological malignancies and chronic graft versus host disease
    Promacta Chronic immune thrombocytopenia purpura and aplastic anemia
    Tremfya Plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease
    Cabometyx/Cometriq Kidney, liver and thyroid cancer
    Spinraza Spinal muscular atrophy
    Trodelvy Breast and bladder cancer
    Erleada Prostate cancer


    Notes

    (1)   Portfolio Receipts is a key performance metric that represents our ability to generate cash from Royalty Pharma’s portfolio investments, the primary source of capital that Royalty Pharma can deploy to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. Royalty Receipts includes variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma (“Royalty Receipts”). Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include royalty receipts and milestones and other contractual receipts that were received on an accelerated basis under the terms of the agreement governing the receipt or payment. Portfolio Receipts also does not include proceeds from equity securities or marketable securities, both of which are not central to Royalty Pharma’s fundamental business strategy.

    Portfolio Receipts is calculated as the sum of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees less Distributions to legacy non-controlling interests – Portfolio Receipts, which represent contractual distributions of Royalty Receipts, milestones and other contractual receipts to the Legacy Investors Partnerships.

    (2)   Adjusted EBITDA is defined under the credit agreement as Portfolio Receipts minus payments for operating and professional costs. Operating and professional costs reflect Payments for operating and professional costs from the GAAP statements of cash flows. See GAAP to Non-GAAP reconciliation in Table 4.

    (3)   Portfolio Cash Flow is defined under the credit agreement as Adjusted EBITDA minus interest paid or received, net. See GAAP to Non-GAAP reconciliation in Table 4. Portfolio Cash Flow reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases or utilized for other discretionary investments.

    (4)   Capital Deployment is calculated as the summation of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Investments in equity method investees, Purchases of available for sale debt securities, Acquisitions of financial royalty assets, Acquisitions of other financial assets, Milestone payments, Development-stage funding payments less Contributions from legacy non-controlling interests – R&D.

    (5)   Other products primarily include Royalty Receipts on the following products: Cimzia, Crysvita, Emgality, Entyvio, Farxiga/Onglyza, IDHIFA, Nesina, Nurtec ODT, Orladeyo, Rytelo, Soliqua, Voranigo and distributions from the Legacy SLP Interest, which is presented as Distributions from equity method investees on the GAAP condensed consolidated statements of cash flows.

    (6)   The table below shows the line item for each adjustment and the direct location for such line item on the GAAP condensed consolidated statements of cash flows.

    Reconciling Adjustment Statements of Cash Flows Classification
    Interest paid, net Operating activities (Interest paid less Interest received)
    Distributions from equity method investees Investing activities
    Proceeds from available for sale debt securities Investing activities
    Distributions to legacy non-controlling interests – Portfolio Receipts Financing activities
       

    (7)   The total transaction value of approximately $1.1 billion is based on the closing price of Royalty Pharma plc common stock of $26.20 on January 8, 2025.

    (8)   Consists of $200 million in cash less the amount of the management fees paid to the Manager from January 1, 2025 through the closing of the transaction.

    The MIL Network –

  • MIL-OSI Europe: Highlights – Presentation of the review of the implementation of HERA operations – Committee on Public Health

    Source: European Parliament

    HERA © image under under the license of AdobeStock

    On 14 May, SANT Members will hear the presentation of the first review of HERA, the Health Emergency Preparedness and Response Authority. It will be followed by the debate on areas of improvement and challenges to address of this first and early review.

    HERA was created as an urgent measure during the Corona pandemic. Today we will discuss what HERA has achieved in response to health threats and in improving preparedness regarding EU health policies.

    MIL OSI Europe News –

  • MIL-OSI Europe: Minutes – Wednesday, 7 May 2025 – Strasbourg – Final edition

    Source: European Parliament

    PV-10-2025-05-07

    EN

    EN

    iPlPv_Sit

    Minutes
    Wednesday, 7 May 2025 – Strasbourg

     Abbreviations and symbols

    + adopted
    – rejected
    ↓ lapsed
    W withdrawn
    RCV roll-call votes
    EV electronic vote
    SEC secret ballot
    split split vote
    sep separate vote
    am amendment
    CA compromise amendment
    CP corresponding part
    D deleting amendment
    = identical amendments
    § paragraph

    IN THE CHAIR: Martin HOJSÍK
    Vice-President

    1. Opening of the sitting

    The sitting opened at 09:00.


    2. Negotiations ahead of Parliament’s first reading (Rule 72) (action taken)

    The decisions of the LIBE and PECH committees and (jointly) the SEDE and ITRE committees to enter into interinstitutional negotiations had been announced on 5 May 2025 (minutes of 5.5.2025, item 12).

    Since no requests for vote had been made pursuant to Rule 72(2), the committees responsible had been able to begin negotiations after the expiry of the deadline set.


    3. EU support for a just, sustainable and comprehensive peace in Ukraine (debate)

    Council and Commission statements: EU support for a just, sustainable and comprehensive peace in Ukraine (2025/2685(RSP))

    Adam Szłapka (President-in-Office of the Council) and Ursula von der Leyen (President of the Commission) made the statements.

    The following spoke: Michael Gahler, on behalf of the PPE Group, Yannis Maniatis, on behalf of the S&D Group, Kinga Gál, on behalf of the PfE Group, Adam Bielan, on behalf of the ECR Group, Petras Auštrevičius, on behalf of the Renew Group, Terry Reintke, on behalf of the Verts/ALE Group, Özlem Demirel, on behalf of The Left Group, Hans Neuhoff, on behalf of the ESN Group, Sandra Kalniete, Thijs Reuten, Harald Vilimsky, who also declined to take a blue-card question from Moritz Körner, Alberico Gambino, Marie-Agnes Strack-Zimmermann, Virginijus Sinkevičius, Marc Botenga, who also answered a blue-card question from Sebastian Tynkkynen, Petar Volgin, Fidias Panayiotou, who also answered a blue-card question from Moritz Körner, Rasa Juknevičienė, Brando Benifei, Tom Vandendriessche, Mirosława Nykiel and Heléne Fritzon.

    IN THE CHAIR: Christel SCHALDEMOSE
    Vice-President

    The following spoke: Beata Szydło, Nathalie Loiseau, Mika Aaltola, Francisco Assis, Hannah Neumann, Paulius Saudargas, Marcos Ros Sempere, Roberto Vannacci, Victor Negrescu, Aurelijus Veryga, Hilde Vautmans, Matej Tonin, Danilo Della Valle, Francisco José Millán Mon, Tonino Picula, Pierre-Romain Thionnet, Salvatore De Meo, Raphaël Glucksmann, Merja Kyllönen, Ingeborg Ter Laak, Elena Yoncheva, Seán Kelly, who also answered a blue-card question from Petras Gražulis, Joanna Scheuring-Wielgus, Tamás Deutsch, Rihards Kols, Helmut Brandstätter, Adrián Vázquez Lázara, Vilija Blinkevičiūtė, Krzysztof Hetman, Jonas Sjöstedt, Danuše Nerudová, Tobias Cremer, Tomasz Buczek, Małgorzata Gosiewska, Dan Barna, Wouter Beke, Ignazio Roberto Marino, Irene Montero and Ana Miguel Pedro.

    The following spoke under the catch-the-eye procedure: Michał Szczerba, Juan Fernando López Aguilar, Viktória Ferenc, Arkadiusz Mularczyk, Dainius Žalimas, Jaume Asens Llodrà, Siegbert Frank Droese, Lukas Sieper, Maria Grapini, Damian Boeselager and Petras Gražulis.

    The following spoke: Valdis Dombrovskis (Member of the Commission) and Adam Szłapka.

    The debate closed.

    (The sitting was suspended at 11:19.)


    IN THE CHAIR: Roberta METSOLA
    President

    4. Resumption of the sitting

    The sitting resumed at 11:35.


    5. Commemoration of the 80th anniversary of the end of World War II in Europe

    The President made a statement to mark the 80th anniversary of the end of World War II in Europe.

    António Costa (President of the European Council), Robert Chot (Member of the Belgian Royal National Federation of War Volunteers), Janusz Komorowski (President of the Polish Association of Home Army Soldiers) and Janusz Maksymowicz (Vice-President of the Warsaw Uprising Insurgents Association), addressed the House.

    The House stood for the European anthem performed by soprano Francesca Sorteni, accompanied by Thomas Gautier and Claire Rigaux on violin, Marie Viard on cello and Emma Errara on viola.

    (The sitting was suspended for a few moments.)


    6. Resumption of the sitting

    The sitting resumed at 12:19.

    ⁂

    The following spoke: Valérie Hayer (the President noted her remarks. She pointed out that serving Europe in the House of democracy was an honourable commitment and called for everyone to respect what this represented).


    7. Welcome

    On behalf of Parliament, the President welcomed Dr Denis Mukwege, winner of the 2014 Sakharov Prize and 2018 Nobel Peace Prize, who had taken his seat in the distinguished visitors’ gallery.


    8. Voting time

    For detailed results of the votes, see also ‘Results of votes’ and ‘Results of roll-call votes’.


    8.1. Amending ERDF, Cohesion Fund and Just Transition Fund as regards specific measures to address strategic challenges in the context of the mid-term review ***I (vote)

    Amending ERDF, Cohesion Fund and Just Transition Fund as regards specific measures to address strategic challenges in the context of the mid-term review – (COM(2025)0123 – C10-0063/2025 – 2025/0084(COD))

    REQUEST FOR AN URGENT DECISION by the REGI Committee (Rule 170(5))

    Approved

    Vote: at a later part-session.

    Detailed voting results


    8.2. European Social Fund (ESF+): specific measures to address strategic challenges ***I (vote)

    European Social Fund (ESF+): specific measures to address strategic challenges – (COM(2025)0164 – C10-0064/2025 – 2025/0085(COD))

    REQUEST FOR AN URGENT DECISION by the EMPL Committee (Rule 170(5))

    Approved

    Vote: at a later part-session.

    Detailed voting results


    8.3. Discharge 2023: EU general budget – Commission, executive agencies and European Development Funds (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section III – Commission, executive agencies and the ninth, tenth and eleventh European Development Funds [COM(2024)0272 – C10-0067/2024 – 2024/2019(DEC)] – Committee on Budgetary Control. Rapporteur: Niclas Herbst (A10-0074/2025)

    (Majority of the votes cast)

    PROPOSALS FOR DECISIONS – Commission and executive agencies

    Adopted (P10_TA(2025)0077)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    PROPOSALS FOR DECISIONS – European Development Funds – EDF (9th, 10th and 11th)

    Adopted (P10_TA(2025)0077)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0077)

    Detailed voting results


    8.4. Discharge 2023: EU general budget – European Parliament (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section I – European Parliament [COM(2024)0272 – C10-0068/2024 – 2024/2020(DEC)] – Committee on Budgetary Control. Rapporteur: Monika Hohlmeier (A10-0062/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0078)

    Detailed voting results


    8.5. Discharge 2023: EU general budget – European Council and Council (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section II – European Council and Council [COM(2024)0272 – C10-0069/2024 – 2024/2021(DEC)] – Committee on Budgetary Control. Rapporteur: Joachim Stanisław Brudziński (A10-0052/2025)

    PROPOSAL FOR A DECISION

    Approved (P10_TA(2025)0079)

    Discharge postponed (see Annex V, Article 5(1)(b) to the Rules of Procedure)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0079)

    Detailed voting results


    8.6. Discharge 2023: EU general budget – Court of Justice of the European Union (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section IV – Court of Justice [COM(2024)0272 – C10-0070/2024 – 2024/2022(DEC)] – Committee on Budgetary Control. Rapporteur: Cristian Terheş (A10-0050/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0080)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0080)

    Detailed voting results


    8.7. Discharge 2023: EU general budget – Court of Auditors (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section V – Court of Auditors [COM(2024)0272 – C10-0071/2024 – 2024/2023(DEC)] – Committee on Budgetary Control. Rapporteur: Dick Erixon (A10-0047/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0081)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0081)

    Detailed voting results


    8.8. Discharge 2023: EU general budget – European Economic and Social Committee (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section VI – European Economic and Social Committee [COM(2024)0272 – C10-0073/2024 – 2024/2025(DEC)] – Committee on Budgetary Control. Rapporteur: Joachim Stanisław Brudziński (A10-0054/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0082)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0082)

    Detailed voting results


    8.9. Discharge 2023: EU general budget – Committee of the Regions (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section VII – Committee of the Regions [COM(2024)0272 – C10-0074/2024 – 2024/2026(DEC)] – Committee on Budgetary Control. Rapporteur: Joachim Stanisław Brudziński (A10-0046/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0083)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0083)

    Detailed voting results


    8.10. Discharge 2023: EU general budget – European Ombudsman (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section VIII – European Ombudsman [COM(2024)0272 – C10-0075/2024 – 2024/2027(DEC)] – Committee on Budgetary Control. Rapporteur: Joachim Stanisław Brudziński (A10-0055/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0084)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0084)

    Detailed voting results


    8.11. Discharge 2023: EU general budget – European Data Protection Supervisor (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section IX – European Data Protection Supervisor [COM(2024)0272 – C10-0076/2024 – 2024/2028(DEC)] – Committee on Budgetary Control. Rapporteur: Joachim Stanisław Brudziński (A10-0053/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0085)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0085)

    Detailed voting results


    8.12. Discharge 2023: EU general budget – European External Action Service (vote)

    Report on discharge in respect of the implementation of the general budget of the European Union for the financial year 2023, Section X – European External Action Service [COM(2024)0272 – C10-0072/2024 – 2024/2024(DEC)] – Committee on Budgetary Control. Rapporteur: Joachim Stanisław Brudziński (A10-0069/2025)

    (Majority of the votes cast)

    PROPOSAL FOR A DECISION

    Adopted (P10_TA(2025)0086)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0086)

    Detailed voting results


    8.13. Discharge 2023: European Public Prosecutor’s Office (vote)

    Report on discharge in respect of the implementation of the budget of the European Public Prosecutor’s Office for the financial year 2023 [COM(2024)0272 – C10-0077/2024 – 2024/2029(DEC)] – Committee on Budgetary Control. Rapporteur: Tomáš Zdechovský (A10-0051/2025)

    (Majority of the votes cast)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0087)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0087)

    Detailed voting results


    8.14. Discharge 2023: Agencies (vote)

    Report on discharge in respect of the implementation of the budget of the European Union Agencies for the financial year 2023 [COM(2024)0272 – C10-0078/2024 – 2024/2030(DEC)] – Committee on Budgetary Control. Rapporteur: Erik Marquardt (A10-0065/2025)

    (Majority of the votes cast)

    European Union Agency for the Cooperation of Energy Regulators (ACER)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Agency for Support for BEREC

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Translation Centre for the Bodies of the European Union (CdT)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Centre for the Development of Vocational Training (Cedefop)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for Law Enforcement Training (CEPOL)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Aviation Safety Agency (EASA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Banking Authority (EBA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Centre for Disease Prevention and Control (ECDC)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Chemicals Agency (ECHA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Environment Agency (EEA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Fisheries Control Agency (EFCA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Food Safety Authority (EFSA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Institute for Gender Equality (EIGE)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Insurance and Occupational Pensions Authority (EIOPA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Institute of Innovation and Technology (EIT)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Labour Authority (ELA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Medicines Agency (EMA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Monitoring Centre for Drugs and Drug Addiction (now European Union Drugs Agency)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Maritime Safety Agency (EMSA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for Cybersecurity (ENISA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for Railways (ERA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Euratom Supply Agency (ESA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Securities and Markets Authority (ESMA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Training Foundation (ETF)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for Asylum (EUAA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge and closure of the accounts was postponed (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for the Operational Management of Large-Scale IT Systems in the Area of Freedom, Security and Justice (eu-LISA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Agency for Safety and Health at Work (EU-OSHA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Foundation for the Improvement of Living and Working Conditions (Eurofound)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for Criminal Justice Cooperation (Eurojust)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for Law Enforcement Cooperation (Europol)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for the Space Programme (EUSPA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Union Agency for Fundamental Rights (FRA)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Border and Coast Guard Agency (Frontex)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0088)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0088)

    Detailed voting results


    8.15. Discharge 2023: Joint Undertakings (vote)

    Report on discharge in respect of the implementation of the budget of the EU joint undertakings for the financial year 2023 [COM(2024)0272 – C10-0079/2024 – 2024/2031(DEC)] – Committee on Budgetary Control. Rapporteur: Michal Wiezik (A10-0056/2025)

    (Majority of the votes cast)

    Clean Aviation Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Circular Bio-based Europe Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Clean Hydrogen Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Europe’s Rail Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European High Performance Computing Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    European Joint Undertaking for ITER and the Development of Fusion Energy

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Global Health EDCTP3 Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Innovative Health Initiative Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Chips Joint Undertaking (before 21.9.2023: Key Digital Technologies Joint Undertaking)

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Single European Sky ATM Research 3 Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    Smart Networks and Services Joint Undertaking

    PROPOSALS FOR DECISIONS

    Adopted (P10_TA(2025)0089)

    Discharge was granted and closure of the accounts approved (see Annex V, Article 5(1) to the Rules of Procedure).

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0089)

    Detailed voting results


    8.16. A revamped long-term budget for the Union in a changing world (vote)

    Report on a revamped long-term budget for the Union in a changing world [2024/2051(INI)] – Committee on Budgets. Rapporteurs: Siegfried Mureşan and Carla Tavares (A10-0076/2025)

    The debate had taken place on 6 May 2025 (minutes of 6.5.2025, item 9).

    (Majority of the votes cast)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0090)

    Detailed voting results


    8.17. The European Water Resilience Strategy (vote)

    Report on the European Water Resilience Strategy [2024/2104(INI)] – Committee on the Environment, Climate and Food Safety. Rapporteur: Thomas Bajada (A10-0073/2025)

    The debate had taken place on 6 May 2025 (minutes of 6.5.2025, item 13).

    (Majority of the votes cast)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0091)

    Detailed voting results


    8.18. 2023 and 2024 reports on Türkiye (vote)

    2023 and 2024 Commission reports on Türkiye [2025/2023(INI)] – Committee on Foreign Affairs. Rapporteur: Nacho Sánchez Amor (A10-0067/2025)

    The debate had taken place on 6 May 2025 (minutes of 6.5.2025, item 14).

    (Majority of the votes cast)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0092)

    The following had spoken:

    Nacho Sánchez Amor (rapporteur), to move an oral amendment to add a new paragraph after paragraph 31. Parliament had agreed to put the oral amendment to the vote.

    Jordan Bardella, to move an oral amendment to add a new paragraph after paragraph 36. Parliament had not agreed to put the oral amendment to the vote as more than 39 Members had opposed it.

    Detailed voting results


    8.19. 2023 and 2024 reports on Serbia (vote)

    Report on the 2023 and 2024 Commission reports on Serbia [2025/2022(INI)] – Committee on Foreign Affairs. Rapporteur: Tonino Picula (A10-0072/2025)

    The debate had taken place on 6 May 2025 (minutes of 6.5.2025, item 16).

    (Majority of the votes cast)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0093)

    The following had spoken:

    Tonino Picula (rapporteur), to move an oral amendment to paragraph 23. Parliament had agreed to put the oral amendment to the vote.

    Detailed voting results


    8.20. 2023 and 2024 reports on Kosovo (vote)

    Report on the 2023 and 2024 Commission Reports on Kosovo [2025/2019(INI)] – Committee on Foreign Affairs. Rapporteur: Riho Terras (A10-0075/2025)

    The debate had taken place on 6 May 2025 (minutes of 6.5.2025, item 17).

    (Majority of the votes cast)

    MOTION FOR A RESOLUTION

    Adopted (P10_TA(2025)0094)

    Detailed voting results

    20

    (The sitting was suspended at 13:39.)


    IN THE CHAIR: Javi LÓPEZ
    Vice-President

    9. Resumption of the sitting

    The sitting resumed at 13:44.


    10. Approval of the minutes of the previous sitting

    The minutes of the previous sitting were approved.


    11. Winning the global tech race: boosting innovation and closing funding gaps (topical debate)

    The following spoke: Eva Maydell to open the debate proposed by the PPE Group.

    The following spoke: Adam Szłapka (President-in-Office of the Council) and Costas Kadis (Member of the Commission).

    The following spoke: Pablo Arias Echeverría, on behalf of the PPE Group, Alex Agius Saliba, on behalf of the S&D Group, Julie Rechagneux, on behalf of the PfE Group, Elena Donazzan, on behalf of the ECR Group, Christophe Grudler, on behalf of the Renew Group, Kim Van Sparrentak, on behalf of the Verts/ALE Group, Leila Chaibi, on behalf of The Left Group, Marcin Sypniewski, on behalf of the ESN Group, Tomislav Sokol, Christel Schaldemose, Kosma Złotowski, Svenja Hahn, David Cormand, Milan Mazurek, Massimiliano Salini, Giorgio Gori, Philippe Olivier, Charlie Weimers, Morten Løkkegaard, Eszter Lakos, Laura Ballarín Cereza, Diego Solier, Fernando Navarrete Rojas, Matthias Ecke, Mario Mantovani and Elena Sancho Murillo.

    The following spoke: Costas Kadis and Adam Szłapka.

    The debate closed.


    12. Competition policy – annual report 2024 (debate)

    Report on competition policy – annual report 2024 [2024/2079(INI)] – Committee on Economic and Monetary Affairs. Rapporteur: Lara Wolters (A10-0071/2025)

    Lara Wolters introduced the report.

    The following spoke: Teresa Ribera (Executive Vice-President of the Commission).

    The following spoke: Andreas Schwab, on behalf of the PPE Group, and Thomas Bajada, on behalf of the S&D Group.

    IN THE CHAIR: Antonella SBERNA
    Vice-President

    The following spoke: Pierre Pimpie, on behalf of the PfE Group, Francesco Ventola, on behalf of the ECR Group, Stéphanie Yon-Courtin, on behalf of the Renew Group, Kira Marie Peter-Hansen, on behalf of the Verts/ALE Group, Martin Schirdewan, on behalf of The Left Group, Rada Laykova, on behalf of the ESN Group, Markus Ferber, René Repasi, Enikő Győri, Marlena Maląg, Marie Toussaint, Marcin Sypniewski, Branislav Ondruš, who also answered a blue-card question from João Oliveira, Georgios Aftias, Nikos Papandreou, Dirk Gotink, Adnan Dibrani, Marco Falcone and Jonás Fernández.

    The following spoke under the catch-the-eye procedure: Ralf Seekatz, Sebastian Tynkkynen, Petras Gražulis, João Oliveira and Alexander Jungbluth.

    The following spoke: Teresa Ribera and Lara Wolters.

    The debate closed.

    Vote: 8 May 2025.


    13. Resilience and the need to improve the interconnection of energy grid infrastructure in the EU: the first lessons from the blackout in the Iberian Peninsula (debate)

    Council and Commission statements: Resilience and the need to improve the interconnection of energy grid infrastructure in the EU: the first lessons from the blackout in the Iberian Peninsula (2025/2686(RSP))

    Adam Szłapka (President-in-Office of the Council) and Dan Jørgensen (Member of the Commission) made the statements.

    The following spoke: Dolors Montserrat, on behalf of the PPE Group, Nicolás González Casares, on behalf of the S&D Group, Jorge Buxadé Villalba, on behalf of the PfE Group, Diego Solier, on behalf of the ECR Group, Anna Stürgkh, on behalf of the Renew Group, Diana Riba i Giner, on behalf of the Verts/ALE Group, Estrella Galán, on behalf of The Left Group, Petr Bystron, on behalf of the ESN Group, Paulo Cunha, who also answered a blue-card question from Petras Gražulis, Francisco Assis, António Tânger Corrêa, who also answered a blue-card question from Bruno Gonçalves, Patryk Jaki, Oihane Agirregoitia Martínez, Jaume Asens Llodrà, Irene Montero, Marc Jongen, Lefteris Nikolaou-Alavanos, François-Xavier Bellamy, who also answered a blue-card question from Nicolás González Casares, Sofie Eriksson, Paolo Borchia, Nora Junco García, Christophe Grudler, Pernando Barrena Arza, Pilar del Castillo Vera, who also declined to take a blue-card question from Nicolás González Casares, and Elena Sancho Murillo.

    IN THE CHAIR: Christel SCHALDEMOSE
    Vice-President

    The following spoke: András Gyürk, Nicolas Bay, Michał Kobosko, João Oliveira, Ana Miguel Pedro, Bruno Gonçalves, Pascale Piera, Daniel Obajtek, Seán Kelly, Bruno Tobback, Georg Mayer, Aleksandar Nikolic and Juan Carlos Girauta Vidal.

    The following spoke under the catch-the-eye procedure: Davor Ivo Stier, Susana Solís Pérez, Sebastian Tynkkynen, Maria Zacharia and Lukas Sieper.

    The following spoke: Dan Jørgensen and Adam Szłapka.

    The debate closed.


    14. High levels of retail food prices and their consequences for European consumers (debate)

    Council and Commission statements: High levels of retail food prices and their consequences for European consumers (2025/2687(RSP))

    Adam Szłapka (President-in-Office of the Council) and Costas Kadis (Member of the Commission) made the statements.

    The following spoke: Tomislav Sokol, on behalf of the PPE Group, Camilla Laureti, on behalf of the S&D Group, Gilles Pennelle, on behalf of the PfE Group, Stefano Cavedagna, on behalf of the ECR Group, Asger Christensen, on behalf of the Renew Group, David Cormand, on behalf of the Verts/ALE Group, Hanna Gedin, on behalf of The Left Group, Milan Mazurek, on behalf of the ESN Group, Carmen Crespo Díaz, Adnan Dibrani, Tomasz Buczek, Veronika Vrecionová, Christine Singer, Ana Miranda Paz, who also answered a blue-card question from João Oliveira, Konstantinos Arvanitis, who also answered a blue-card question from Rody Tolassy, Kateřina Konečná, Péter Magyar, Biljana Borzan, Marieke Ehlers, Sergio Berlato, Ciaran Mullooly, Marc Botenga, Nikolaos Anadiotis, Krzysztof Hetman, Pierfrancesco Maran, Barbara Bonte, Jessika Van Leeuwen, Laura Ballarín Cereza, Margarita de la Pisa Carrión and France Jamet.

    IN THE CHAIR: Esteban GONZÁLEZ PONS
    Vice-President

    The following spoke under the catch-the-eye procedure: Cristina Maestre, Mireia Borrás Pabón, Csaba Dömötör, Sebastian Tynkkynen, Rasmus Andresen, Elena Kountoura, João Oliveira, Lukas Sieper and Maria Zacharia.

    The following spoke: Costas Kadis and Adam Szłapka.

    The debate closed.


    15. Malta’s Golden Passport scheme circumventing EU sanctions against Russia (debate)

    Council and Commission statements: Malta’s Golden Passport scheme circumventing EU sanctions against Russia (2025/2688(RSP))

    Adam Szłapka (President-in-Office of the Council) and Michael McGrath (Member of the Commission) made the statements.

    The following spoke: David Casa, on behalf of the PPE Group, Alex Agius Saliba, on behalf of the S&D Group, Jadwiga Wiśniewska, on behalf of the ECR Group, Raquel García Hermida-Van Der Walle, on behalf of the Renew Group, Saskia Bricmont, on behalf of the Verts/ALE Group, Giuseppe Antoci, on behalf of The Left Group, Luděk Niedermayer, Birgit Sippel, Georgiana Teodorescu, who also declined to take a blue-card question from Raquel García Hermida-Van Der Walle, Irena Joveva, Daniel Freund, Peter Agius, Thomas Bajada, who also answered a blue-card question from Raquel García Hermida-Van Der Walle and did not accept a blue-card question from Daniel Freund, Alice Teodorescu Måwe, Daniel Attard, who also answered a blue-card question from Daniel Freund, and Evelyn Regner.

    The following spoke under the catch-the-eye procedure: Juan Fernando López Aguilar and Sebastian Tynkkynen.

    The following spoke: Alex Agius Saliba (the President cut off the speaker as his remarks did not constitute a point of order).

    The following spoke under the catch-the-eye procedure: Maria Zacharia.

    The following spoke: Michael McGrath and Adam Szłapka.

    The debate closed.


    16. The role of gas storage for securing gas supplies ahead of the winter season (debate)

    Report on the proposal for a regulation of the European Parliament and of the Council amending Regulation (EU) 2017/1938 as regards the role of gas storage for securing gas supplies ahead of the winter season [COM(2025)0099 – C10-0041/2025 – 2025/0051(COD)] – Committee on Industry, Research and Energy. Rapporteur: Borys Budka (A10-0079/2025)

    Borys Budka introduced the report.

    The following spoke: Dan Jørgensen (Member of the Commission).

    The following spoke: Andrea Wechsler, on behalf of the PPE Group, Jens Geier, on behalf of the S&D Group, András Gyürk, on behalf of the PfE Group, Ondřej Krutílek, on behalf of the ECR Group, Yvan Verougstraete, on behalf of the Renew Group, Marie Toussaint, on behalf of the Verts/ALE Group, Dario Tamburrano, on behalf of The Left Group, Alexander Sell, on behalf of the ESN Group, Jüri Ratas, Nicolás González Casares, Julie Rechagneux, Michael Bloss, Thomas Geisel and Mirosława Nykiel.

    IN THE CHAIR: Ewa KOPACZ
    Vice-President

    The following spoke: Michalis Hadjipantela and Virgil-Daniel Popescu.

    The following spoke under the catch-the-eye procedure: Liudas Mažylis, Sebastian Tynkkynen, Marta Wcisło and Billy Kelleher.

    The following spoke: Dan Jørgensen and Borys Budka.

    The debate closed.

    Vote: 8 May 2025.


    17. Banking Union – annual report 2024 (debate)

    Report on Banking Union – annual report 2024 [2024/2055(INI)] – Committee on Economic and Monetary Affairs. Rapporteur: Ralf Seekatz (A10-0044/2025)

    Ralf Seekatz introduced the report.

    The following spoke: Michael McGrath (Member of the Commission).

    The following spoke: Marco Falcone, on behalf of the PPE Group, Jonás Fernández, on behalf of the S&D Group, Marlena Maląg, on behalf of the ECR Group, Billy Kelleher, on behalf of the Renew Group, Jussi Saramo, on behalf of The Left Group, Costas Mavrides and Giovanni Crosetto.

    The following spoke under the catch-the-eye procedure: Marta Wcisło, Sebastian Tynkkynen and Lukas Sieper.

    The following spoke: Michael McGrath and Ralf Seekatz.

    The debate closed.

    Vote: 8 May 2025.


    18. The fine against TikTok and the need to strengthen the protection of citizens’ rights on social media platforms (debate)

    Commission statement: The fine against TikTok and the need to strengthen the protection of citizens’ rights on social media platforms (2025/2704(RSP))

    Michael McGrath (Member of the Commission) made the statement.

    The following spoke: François-Xavier Bellamy, on behalf of the PPE Group, Alex Agius Saliba, on behalf of the S&D Group, Virginie Joron, on behalf of the PfE Group, Gheorghe Piperea, on behalf of the ECR Group, Veronika Cifrová Ostrihoňová, on behalf of the Renew Group, Alexandra Geese, on behalf of the Verts/ALE Group, Konstantinos Arvanitis, on behalf of The Left Group, Mary Khan, Pablo Arias Echeverría, Elisabeth Dieringer, Sandro Gozi, Fidias Panayiotou, Sunčana Glavak, Cynthia Ní Mhurchú and Moritz Körner.

    The following spoke under the catch-the-eye procedure: Juan Fernando López Aguilar, Billy Kelleher and Lukas Sieper.

    The following spoke: Michael McGrath.

    The debate closed.


    19. Debate on cases of breaches of human rights, democracy and the rule of law (debate)

    (For the titles and authors of the motions for resolutions, see minutes of 7.5.2025, item I.)


    19.1. Arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania

    Motions for resolutions B10-0260/2025, B10-0261/2025, B10-0262/2025, B10-0263/2025, B10-0264/2025 and B10-0265/2025 (2025/2690(RSP))

    Reinhold Lopatka, Marit Maij, Jan-Christoph Oetjen, Catarina Vieira and Tomasz Froelich introduced their groups’ motions for resolutions.

    The following spoke under the catch-the-eye procedure: Lukas Sieper.

    The following spoke: Michael McGrath (Member of the Commission).

    The debate closed.

    Vote: 8 May 2025.


    19.2. Return of Ukrainian children forcibly transferred and deported by Russia

    Motions for resolutions B10-0247/2025, B10-0249/2025, B10-0250/2025, B10-0252/2025, B10-0255/2025 and B10-0258/2025 (2025/2691(RSP))

    Jessika Van Leeuwen, Thijs Reuten, Petras Auštrevičius, Villy Søvndal and Małgorzata Gosiewska introduced their groups’ motions for resolutions.

    The following spoke: Michał Szczerba, on behalf of the PPE Group, and Pina Picierno, on behalf of the S&D Group.

    IN THE CHAIR: Antonella SBERNA
    Vice-President

    The following spoke: Karin Karlsbro, on behalf of the Renew Group, Ingeborg Ter Laak, Sandra Gómez López, Charles Goerens, Lukas Mandl, Pierfrancesco Maran, Isabel Wiseler-Lima, Davor Ivo Stier and Alice Teodorescu Måwe.

    The following spoke under the catch-the-eye procedure: Liudas Mažylis, Nikos Papandreou, Lukas Sieper and Marta Wcisło.

    The following spoke: Michael McGrath (Member of the Commission).

    The debate closed.

    Vote: 8 May 2025.


    19.3. Violations of religious freedom in Tibet

    Motions for resolutions B10-0248/2025, B10-0251/2025, B10-0253/2025, B10-0254/2025, B10-0256/2025 and B10-0259/2025 (2025/2692(RSP))

    Danuše Nerudová, Hannes Heide, Mariusz Kamiński, Engin Eroglu and Ville Niinistö introduced their groups’ motions for resolutions.

    The following spoke: Michael McNamara, on behalf of the Renew Group.

    The following spoke under the catch-the-eye procedure: Vytenis Povilas Andriukaitis and Lukas Sieper.

    The following spoke: Michael McNamara, on the previous speaker’s comments, and Lukas Sieper on Michael McNamara’s contribution.

    The following spoke: Michael McGrath (Member of the Commission).

    The debate closed.

    Vote: 8 May 2025.


    20. Democratic legitimacy and the Commission’s continued authorisation of genetically modified organisms despite Parliament’s objections (debate)

    Commission statement: Democratic legitimacy and the Commission’s continued authorisation of genetically modified organisms despite Parliament’s objections (2025/2645(RSP))

    Olivér Várhelyi (Member of the Commission) made the statement.

    The following spoke: Esther Herranz García, on behalf of the PPE Group, Biljana Borzan, on behalf of the S&D Group, Paolo Inselvini, on behalf of the ECR Group, Martin Häusling, on behalf of the Verts/ALE Group, Nikolas Farantouris, on behalf of The Left Group, Daniel Buda, Maria Noichl, Georgiana Teodorescu and Günther Sidl.

    The following spoke under the catch-the-eye procedure: Kristian Vigenin, Diana Iovanovici Şoşoacă, Vytenis Povilas Andriukaitis and Lukas Sieper.

    The following spoke: Olivér Várhelyi.

    The debate closed.


    21. The illegal visit of President Erdoğan to the occupied areas of Cyprus (debate)

    Council and Commission statements: The illegal visit of President Erdoğan to the occupied areas of Cyprus (2025/2705(RSP))

    Michael McGrath (Member of the Commission) made the statement on behalf of the Commission.

    The following spoke: Loucas Fourlas, on behalf of the PPE Group, Costas Mavrides, on behalf of the S&D Group, Afroditi Latinopoulou, on behalf of the PfE Group, Geadis Geadi, on behalf of the ECR Group (the President reminded the speaker of the rules on conduct), Kai Tegethoff, on behalf of the Verts/ALE Group, and Irene Montero, on behalf of The Left Group.

    The following spoke: Michael McGrath.

    The debate closed.


    22. Explanations of vote


    22.1. Discharge 2023: EU general budget – European External Action Service (A10-0069/2025 – Joachim Stanisław Brudziński) (oral explanations of vote)

    Lynn Boylan


    22.2. Written explanations of vote

    Explanations of vote submitted in writing under Rule 201 appear on the Members’ pages on Parliament’s website.


    23. Agenda of the next sitting

    The next sitting would be held the following day, 8 May 2025, starting at 09:00. The agenda was available on Parliament’s website.


    24. Approval of the minutes of the sitting

    In accordance with Rule 208(3), the minutes of the sitting would be put to the House for approval at the beginning of the afternoon of the next sitting.


    25. Closure of the sitting

    The sitting closed at 22:21.


    LIST OF DOCUMENTS SERVING AS A BASIS FOR THE DEBATES AND DECISIONS OF PARLIAMENT


    I. Motions for resolutions tabled

    Arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania

    The following Members or political groups had requested that a debate be held, in accordance with Rule 150, on the following motions for resolutions:

    on the arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania (2025/2690(RSP)) (B10-0260/2025)
    Catarina Vieira, Nicolae Ştefănuță, Mounir Satouri, Maria Ohisalo, Mélissa Camara, Ville Niinistö
    on behalf of the Verts/ALE Group

    on the arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania (2025/2690(RSP)) (B10-0261/2025)
    Yannis Maniatis, Francisco Assis, Marit Maij
    on behalf of the S&D Group

    on the arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania (2025/2690(RSP)) (B10-0262/2025)
    Tomasz Froelich
    on behalf of the ESN Group

    on the arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania (2025/2690(RSP)) (B10-0263/2025)
    Jan-Christoph Oetjen, Oihane Agirregoitia Martínez, Petras Auštrevičius, Malik Azmani, Dan Barna, Benoit Cassart, Olivier Chastel, Engin Eroglu, Svenja Hahn, Ilhan Kyuchyuk, Karin Karlsbro, Moritz Körner, Urmas Paet, Marie-Agnes Strack-Zimmermann, Hilde Vautmans, Michal Wiezik, Lucia Yar
    on behalf of the Renew Group

    on the arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania (2025/2690(RSP)) (B10-0264/2025)
    Sebastião Bugalho, Reinhold Lopatka, Michael Gahler, David McAllister, Antonio López-Istúriz White, Ana Miguel Pedro, Davor Ivo Stier, Tomas Tobé, Liudas Mažylis, Ingeborg Ter Laak, Isabel Wiseler-Lima, Mirosława Nykiel, Wouter Beke, Luděk Niedermayer, Vangelis Meimarakis, Milan Zver, Tomáš Zdechovský, Danuše Nerudová, Miriam Lexmann, Jan Farský, Loránt Vincze, Jessica Polfjärd, Andrey Kovatchev, Inese Vaidere
    on behalf of the PPE Group

    on the arrest and risk of execution of Tundu Lissu, Chair of Chadema, the main opposition party in Tanzania (2025/2690(RSP)) (B10-0265/2025)
    Adam Bielan, Sebastian Tynkkynen, Waldemar Tomaszewski, Ondřej Krutílek, Veronika Vrecionová, Alexandr Vondra, Joachim Stanisław Brudziński, Ivaylo Valchev, Jadwiga Wiśniewska, Assita Kanko, Alberico Gambino, Carlo Fidanza
    on behalf of the ECR Group

    Return of Ukrainian children forcibly transferred and deported by Russia

    The following Members or political groups had requested that a debate be held, in accordance with Rule 150, on the following motions for resolutions:

    on the return of Ukrainian children forcibly transferred and deported by Russia (2025/2691(RSP)) (B10-0247/2025)
    Merja Kyllönen
    on behalf of The Left Group

    on the return of Ukrainian children forcibly transferred and deported by Russia (2025/2691(RSP)) (B10-0249/2025)
    Villy Søvndal, Sergey Lagodinsky, Nicolae Ştefănuță, Mounir Satouri, Maria Ohisalo, Catarina Vieira, Ville Niinistö
    on behalf of the Verts/ALE Group

    on the return of Ukrainian children forcibly transferred and deported by Russia (2025/2691(RSP)) (B10-0250/2025)
    Yannis Maniatis, Francisco Assis, Thijs Reuten, Evin Incir, Pina Picierno
    on behalf of the S&D Group

    on the return of Ukrainian children forcibly transferred and deported by Russia (2025/2691(RSP)) (B10-0252/2025)
    Petras Auštrevičius, Oihane Agirregoitia Martínez, Abir Al-Sahlani, Malik Azmani, Dan Barna, Helmut Brandstätter, Benoit Cassart, Olivier Chastel, Veronika Cifrová Ostrihoňová, Engin Eroglu, Svenja Hahn, Karin Karlsbro, Ľubica Karvašová, Moritz Körner, Ilhan Kyuchyuk, Nathalie Loiseau, Jan-Christoph Oetjen, Urmas Paet, Marie-Agnes Strack-Zimmermann, Eugen Tomac, Hilde Vautmans, Lucia Yar, Michał Kobosko
    on behalf of the Renew Group

    on the return of Ukrainian children forcibly transferred and deported by Russia (2025/2691(RSP)) (B10-0255/2025)
    Sebastião Bugalho, Jessika Van Leeuwen, Michael Gahler, David McAllister, Sandra Kalniete, Andrzej Halicki, Antonio López-Istúriz White, Ana Miguel Pedro, Dariusz Joński, Davor Ivo Stier, Tomas Tobé, Reinhold Lopatka, Liudas Mažylis, Ingeborg Ter Laak, Isabel Wiseler-Lima, Mirosława Nykiel, Wouter Beke, Luděk Niedermayer, Vangelis Meimarakis, Milan Zver, Tomáš Zdechovský, Danuše Nerudová, Miriam Lexmann, Ondřej Kolář, Jan Farský, Loránt Vincze, Jessica Polfjärd, Andrey Kovatchev, Ewa Kopacz, Matej Tonin, Inese Vaidere
    on behalf of the PPE Group

    on the return of Ukrainian children forcibly transferred and deported by Russia (2025/2691(RSP)) (B10-0258/2025)
    Adam Bielan, Mariusz Kamiński, Małgorzata Gosiewska, Sebastian Tynkkynen, Michał Dworczyk, Veronika Vrecionová, Ondřej Krutílek, Jaak Madison, Alexandr Vondra, Arkadiusz Mularczyk, Bogdan Rzońca, Roberts Zīle, Ivaylo Valchev, Joachim Stanisław Brudziński, Assita Kanko, Aurelijus Veryga, Jadwiga Wiśniewska, Rihards Kols, Maciej Wąsik, Marlena Maląg, Charlie Weimers, Cristian Terheş
    on behalf of the ECR Group

    Violations of religious freedom in Tibet

    The following Members or political groups had requested that a debate be held, in accordance with Rule 150, on the following motions for resolutions:

    on the violations of religious freedom in Tibet (2025/2692(RSP)) (B10-0248/2025)
    Ville Niinistö, Catarina Vieira, Maria Ohisalo, Erik Marquardt, Nicolae Ştefănuță, Mounir Satouri, Leoluca Orlando
    on behalf of the Verts/ALE Group

    on the violations of religious freedom in Tibet (2025/2692(RSP)) (B10-0251/2025)
    Yannis Maniatis, Francisco Assis, Hannes Heide
    on behalf of the S&D Group

    on the violations of religious freedom in Tibet (2025/2692(RSP)) (B10-0253/2025)
    Hermann Tertsch, Jorge Martín Frías, Jaroslav Bžoch, Susanna Ceccardi
    on behalf of the PfE Group

    on the violations of religious freedom in Tibet (2025/2692(RSP)) (B10-0254/2025)
    Engin Eroglu, Oihane Agirregoitia Martínez, Petras Auštrevičius, Malik Azmani, Dan Barna, Helmut Brandstätter, Benoit Cassart, Olivier Chastel, Bernard Guetta, Svenja Hahn, Ľubica Karvašová, Moritz Körner, Ilhan Kyuchyuk, Nathalie Loiseau, Karin Karlsbro, Jan-Christoph Oetjen, Marie-Agnes Strack-Zimmermann, Lucia Yar, Dainius Žalimas
    on behalf of the Renew Group

    on the violations of religious freedom in Tibet (2025/2692(RSP)) (B10-0256/2025)
    Sebastião Bugalho, Danuše Nerudová, Michael Gahler, Antonio López-Istúriz White, Ana Miguel Pedro, Davor Ivo Stier, Tomas Tobé, Reinhold Lopatka, Liudas Mažylis, Ingeborg Ter Laak, Isabel Wiseler-Lima, Mirosława Nykiel, Wouter Beke, Luděk Niedermayer, Vangelis Meimarakis, Milan Zver, Tomáš Zdechovský, Miriam Lexmann, Ondřej Kolář, Jan Farský, Loránt Vincze, Jessica Polfjärd, Andrey Kovatchev, Inese Vaidere
    on behalf of the PPE Group

    on the violations of religious freedom in Tibet (2025/2692(RSP)) (B10-0259/2025)
    Adam Bielan, Mariusz Kamiński, Waldemar Tomaszewski, Alberico Gambino, Sebastian Tynkkynen, Carlo Fidanza, Małgorzata Gosiewska, Ondřej Krutílek, Veronika Vrecionová, Assita Kanko, Michał Dworczyk, Arkadiusz Mularczyk, Bogdan Rzońca, Alexandr Vondra, Joachim Stanisław Brudziński, Jadwiga Wiśniewska, Maciej Wąsik, Marlena Maląg
    on behalf of the ECR Group


    II. Delegated acts (Rule 114(2))

    Draft delegated acts forwarded to Parliament

    – Commission Delegated Regulation supplementing Regulation (EU) 2023/2631 of the European Parliament and of the Council by establishing the content, methodologies, and presentation of the information to be voluntarily disclosed by issuers of bonds marketed as environmentally sustainable or of sustainability-linked bonds in the templates for periodic post-issuance disclosures (C(2025)00005 – 2025/2674(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 16 April 2025

    referred to committee responsible: ECON

    – Commission Delegated Regulation supplementing Regulation (EU) 2023/2631of the European Parliament and of the Council by specifying rules of procedure for the exercise of the power to impose fines or periodic penalty payments by the European Securities and Markets Authority on external reviewers (C(2025)00006 – 2025/2676(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 16 April 2025

    referred to committee responsible: ECON

    – Commission Delegated Regulation supplementing Regulation (EU) 2023/2631 of the European Parliament and of the Council by specifying the type of fees to be charged by ESMA to external reviewers of European Green Bonds, the matters in respect of which fees are due, the amount of the fees, and the manner in which those fees are to be paid (C(2025)00007 – 2025/2677(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 16 April 2025

    referred to committee responsible: ECON

    – Commission Delegated Regulation supplementing Directive 2013/36/EU of the European Parliament and of the Council with regard to regulatory technical standards specifying the general conditions for the functioning of supervisory colleges, and repealing Commission Delegated Regulation (EU) 2016/98 (C(2025)00701 – 2025/2678(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 23 April 2025

    referred to committee responsible: ECON

    – Commission Delegated Regulation amending Regulation (EU) 2023/1804 of the European Parliament and of the Council as regards additional data types on alternative fuels infrastructure (C(2025)01912 – 2025/2661(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 2 April 2025

    referred to committee responsible: TRAN

    – Commission Delegated Regulation supplementing Regulation (EU) 2023/1804 of the European Parliament and of the Council as regards common technical requirements for a common application programme interface (C(2025)01913 – 2025/2659(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 2 April 2025

    referred to committee responsible: TRAN

    – Commission Delegated Regulation amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council as regards the harmonised classification and labelling of certain substances (C(2025)01916 – 2025/2660(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 2 April 2025

    referred to committee responsible: ENVI
    opinion: IMCO

    – Commission Delegated Regulation amending Regulation (EU) 2023/1804 of the European Parliament and of the Council as regards standards for wireless recharging, electric road system, vehicle-to-grid communication and hydrogen supply for road transport vehicles (C(2025)01918 – 2025/2662(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 2 April 2025

    referred to committee responsible: TRAN

    – Commission Delegated Regulation amending Delegated Regulation (EU) 2015/68 and Delegated Regulation (EU) 2015/208 with regard to vehicle braking requirements and to vehicle functional safety requirements for agricultural and forestry vehicles (C(2025)01944 – 2025/2663(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 3 April 2025

    referred to committee responsible: IMCO

    – Commission Delegated Regulation amending Delegated Regulation (EU) 2023/205 as regards the European Maritime Single Window environment data set (C(2025)02021 – 2025/2667(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 7 April 2025

    referred to committee responsible: TRAN

    – Commission Delegated Regulation supplementing Regulation (EU) No 305/2011 of the European Parliament and of the Council by establishing threshold levels and classes of performance for permanent anchor devices and safety hooks (C(2025)02119 – 2025/2670(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 9 April 2025

    referred to committee responsible: IMCO

    – Commission Delegated Directive amending Directive 2005/36/EC of the European Parliament and of the Council as regards the minimum training requirements for the profession of veterinary surgeon (C(2025)02128 – 2025/2671(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 10 April 2025

    referred to committee responsible: IMCO

    – Commission Delegated Regulation amending Regulation (EU) 2019/1021 of the European Parliament and of the Council as regards perfluorooctane sulfonic acid and its derivatives (C(2025)02189 – 2025/2672(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 14 April 2025

    referred to committee responsible: ENVI

    – Commission delegated decision on the unilateral inclusion of sectors by Finland in the emissions trading system within the Union for buildings, road transport and additional sectors pursuant to Article 30j of Directive 2003/87/EC of the European Parliament and of the Council (C(2025)02232 – 2025/2673(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 15 April 2025

    referred to committee responsible: ENVI
    opinion: ITRE

    – Commission Delegated Regulation amending Delegated Regulation (EU) 2023/2197 as regards the date of application (C(2025)02258 – 2025/2675(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 16 April 2025

    referred to committee responsible: SANT

    – Commission Delegated Regulation supplementing Regulation (EU) No 575/2013 of the European Parliament and of the Council with regard to regulatory technical standards specifying the conditions and indicators that the EBA is to use to determine whether extraordinary circumstances in the sense of Article 325az(5) and Article 325bf(6) of that Regulation have occurred (C(2025)02287 – 2025/2679(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 23 April 2025

    referred to committee responsible: ECON

    – Commission Delegated Regulation supplementing Regulation (EU) 2023/1114 of the European Parliament and of the Council with regard to regulatory technical standards specifying the arrangements, systems and procedures to prevent, detect and report market abuse, the templates to be used for reporting suspected market abuse, and the coordination procedures between the competent authorities for the detection and sanctioning of market abuse in cross-border market abuse situations (C(2025)02480 – 2025/2684(DEA))

    Deadline for raising objections: 3 months from the date of receipt of 29 April 2025

    referred to committee responsible: ECON

    – Commission Delegated Regulation amending Annex I to Regulation (EU) 2019/1021 of the European Parliament and of the Council as regards perfluorooctanoic acid (PFOA), its salts and PFOA-related compounds (C(2025)02566 – 2025/2701(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 5 May 2025

    referred to committee responsible: ENVI

    – Commission Delegated Regulation (EU)…/ … amending Annex I to Regulation (EU) 2019/1021 of the European Parliament and of the Council as regards UV-328 (C(2025)02567 – 2025/2703(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 5 May 2025

    referred to committee responsible: ENVI

    – Commission Delegated Regulation amending Delegated Regulation (EU) 2024/2910 on the implementation of the Union’s international obligations, as referred to in Article 15(2) of Regulation (EU) No 1380/2013 of the European Parliament and of the Council, under the General Fisheries Commission for the Mediterranean (C(2025)02570 – 2025/2702(DEA))

    Deadline for raising objections: 2 months from the date of receipt of 5 May 2025

    referred to committee responsible: PECH


    III. Implementing measures (Rule 115)

    Draft implementing measures falling under the regulatory procedure with scrutiny forwarded to Parliament

    – Commission Regulation correcting certain language versions of Regulation (EU) No 142/2011 implementing Regulation (EC) No 1069/2009 of the European Parliament and of the Council laying down health rules as regards animal by-products and derived products not intended for human consumption and implementing Council Directive 97/78/EC as regards certain samples and items exempt from veterinary checks at the border under that Directive (D010438/05 – 2025/2693(RPS) – deadline: 22 July 2025)
    referred to committee responsible: ENVI
    opinion: AGRI

    – Commission Regulation amending Annex II to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for acetamiprid in or on certain products (D102375/03 – 2025/2664(RPS) – deadline: 4 June 2025)
    referred to committee responsible: ENVI

    – Commission Regulation amending Annex III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council as regards the use of polyvinylpolypyrrolidone (E 1202) as a carrier in colour tablets for the decorative colouring of poultry eggshells (D106245/02 – 2025/2680(RPS) – deadline: 29 June 2025)
    referred to committee responsible: ENVI

    – Commission Regulation amending Regulation (EU) 2023/915 as regards maximum levels of inorganic arsenic in fish and other seafood (D106246/02 – 2025/2681(RPS) – deadline: 29 July 2025)
    referred to committee responsible: ENVI


    IV. Documents received

    The following documents had been received from other institutions:

    – Proposal for transfer of appropriations DEC 05/2025 – Section III – Commission (N10-0013/2025 – C10-0065/2025 – 2025/2078(GBD))
    referred to committee responsible: BUDG

    – Proposal for transfer of appropriations INF 1/2025 – Section VI – Economic and Social Committee (N10-0014/2025 – C10-0078/2025 – 2025/2091(GBD))
    referred to committee responsible: BUDG

    – Proposal for transfer of appropriations No. 2/2025 – Section IX – European Data Protection Supervisor (N10-0015/2025 – C10-0079/2025 – 2025/2092(GBD))
    referred to committee responsible: BUDG


    V. Transfers of appropriations and budgetary decisions

    In accordance with Article 31(1) of the Financial Regulation, the Committee on Budgets had decided to approve the European Commission’s transfers of appropriations DEC 03/2025 and DEC 04/2025 – Section III – Commission.

    In accordance with Article 31(6) of the Financial Regulation, the Council of the European Union had decided to approve the European Commission’s transfers of appropriations DEC 03/2025 and DEC 04/2025 – Section III – Commission.


    ATTENDANCE REGISTER

    Present:

    Aaltola Mika, Abadía Jover Maravillas, Adamowicz Magdalena, Aftias Georgios, Agirregoitia Martínez Oihane, Agius Peter, Agius Saliba Alex, Alexandraki Galato, Allione Grégory, Al-Sahlani Abir, Anadiotis Nikolaos, Anderson Christine, Andersson Li, Andresen Rasmus, Andrews Barry, Andriukaitis Vytenis Povilas, Androuët Mathilde, Angel Marc, Annemans Gerolf, Annunziata Lucia, Antoci Giuseppe, Arias Echeverría Pablo, Arimont Pascal, Arłukowicz Bartosz, Arnaoutoglou Sakis, Arndt Anja, Arvanitis Konstantinos, Asens Llodrà Jaume, Assis Francisco, Attard Daniel, Aubry Manon, Auštrevičius Petras, Axinia Adrian-George, Azmani Malik, Bajada Thomas, Baljeu Jeannette, Ballarín Cereza Laura, Bardella Jordan, Barna Dan, Barrena Arza Pernando, Bartulica Stephen Nikola, Bartůšek Nikola, Bay Nicolas, Bay Christophe, Beke Wouter, Beleris Fredis, Bellamy François-Xavier, Benea Dragoş, Benifei Brando, Benjumea Benjumea Isabel, Beňová Monika, Berendsen Tom, Berger Stefan, Berlato Sergio, Bernhuber Alexander, Biedroń Robert, Bielan Adam, Bischoff Gabriele, Blaha Ľuboš, Blinkevičiūtė Vilija, Blom Rachel, Bloss Michael, Bocheński Tobiasz, Boeselager Damian, Bogdan Ioan-Rareş, Bonaccini Stefano, Bonte Barbara, Borchia Paolo, Borrás Pabón Mireia, Borvendég Zsuzsanna, Borzan Biljana, Bosanac Gordan, Boßdorf Irmhild, Bosse Stine, Botenga Marc, Boyer Gilles, Boylan Lynn, Brandstätter Helmut, Brasier-Clain Marie-Luce, Bricmont Saskia, Brnjac Nikolina, Brudziński Joachim Stanisław, Bryłka Anna, Buchheit Markus, Buczek Tomasz, Buda Daniel, Buda Waldemar, Budka Borys, Bugalho Sebastião, Buła Andrzej, Bullmann Udo, Burkhardt Delara, Buxadé Villalba Jorge, Bystron Petr, Bžoch Jaroslav, Camara Mélissa, Canfin Pascal, Carberry Nina, Cârciu Gheorghe, Carême Damien, Casa David, Caspary Daniel, Cassart Benoit, Castillo Laurent, del Castillo Vera Pilar, Cavazzini Anna, Cavedagna Stefano, Cepeda José, Ceulemans Estelle, Chahim Mohammed, Chaibi Leila, Chastel Olivier, Chinnici Caterina, Christensen Asger, Ciccioli Carlo, Cifrová Ostrihoňová Veronika, Ciriani Alessandro, Cisint Anna Maria, Clausen Per, Clergeau Christophe, Cormand David, Corrado Annalisa, Costanzo Vivien, Cotrim De Figueiredo João, Cowen Barry, Cremer Tobias, Crespo Díaz Carmen, Cristea Andi, Crosetto Giovanni, Cunha Paulo, Dahl Henrik, Danielsson Johan, Dauchy Marie, Dávid Dóra, David Ivan, Decaro Antonio, de la Hoz Quintano Raúl, Della Valle Danilo, Deloge Valérie, De Masi Fabio, De Meo Salvatore, Demirel Özlem, Deutsch Tamás, Devaux Valérie, Dibrani Adnan, Diepeveen Ton, Dieringer Elisabeth, Dîncu Vasile, Di Rupo Elio, Disdier Mélanie, Dobrev Klára, Doherty Regina, Doleschal Christian, Dömötör Csaba, Do Nascimento Cabral Paulo, Donazzan Elena, Dorfmann Herbert, Dostalova Klara, Dostál Ondřej, Droese Siegbert Frank, Dworczyk Michał, Ecke Matthias, Ehler Christian, Ehlers Marieke, Eriksson Sofie, Erixon Dick, Eroglu Engin, Estaràs Ferragut Rosa, Everding Sebastian, Falcă Gheorghe, Falcone Marco, Farantouris Nikolas, Farreng Laurence, Farský Jan, Ferber Markus, Ferenc Viktória, Fernández Jonás, Fidanza Carlo, Fiocchi Pietro, Firea Gabriela, Firmenich Ruth, Fita Claire, Fourlas Loucas, Fourreau Emma, Fragkos Emmanouil, Freund Daniel, Frigout Anne-Sophie, Fritzon Heléne, Froelich Tomasz, Fuglsang Niels, Funchion Kathleen, Furet Angéline, Furore Mario, Gahler Michael, Gál Kinga, Galán Estrella, Gálvez Lina, Gambino Alberico, García Hermida-Van Der Walle Raquel, Garraud Jean-Paul, Gasiuk-Pihowicz Kamila, Geadi Geadis, Gedin Hanna, Geese Alexandra, Geier Jens, Geisel Thomas, Gemma Chiara, Georgiou Giorgos, Gerbrandy Gerben-Jan, Germain Jean-Marc, Gerzsenyi Gabriella, Geuking Niels, Gieseke Jens, Giménez Larraz Borja, Girauta Vidal Juan Carlos, Glavak Sunčana, Glück Andreas, Glucksmann Raphaël, Goerens Charles, Gomart Christophe, Gomes Isilda, Gómez López Sandra, Gonçalves Bruno, Gonçalves Sérgio, González Casares Nicolás, González Pons Esteban, Gori Giorgio, Gosiewska Małgorzata, Gotink Dirk, Gozi Sandro, Grapini Maria, Gražulis Petras, Grims Branko, Griset Catherine, Gronkiewicz-Waltz Hanna, Groothuis Bart, Grossmann Elisabeth, Grudler Christophe, Gualmini Elisabetta, Guarda Cristina, Győri Enikő, Gyürk András, Hadjipantela Michalis, Hahn Svenja, Haider Roman, Halicki Andrzej, Hansen Niels Flemming, Hauser Gerald, Häusling Martin, Hava Mircea-Gheorghe, Heide Hannes, Heinäluoma Eero, Henriksson Anna-Maja, Herbst Niclas, Herranz García Esther, Hetman Krzysztof, Hohlmeier Monika, Hojsík Martin, Holmgren Pär, Hölvényi György, Homs Ginel Alicia, Humberto Sérgio, Imart Céline, Incir Evin, Inselvini Paolo, Iovanovici Şoşoacă Diana, Jamet France, Jarubas Adam, Jerković Romana, Jongen Marc, Joński Dariusz, Joron Virginie, Jouvet Pierre, Joveva Irena, Juknevičienė Rasa, Junco García Nora, Jungbluth Alexander, Kabilov Taner, Kalfon François, Kaliňák Erik, Kaljurand Marina, Kalniete Sandra, Kamiński Mariusz, Karlsbro Karin, Kartheiser Fernand, Karvašová Ľubica, Katainen Elsi, Kefalogiannis Emmanouil, Kelleher Billy, Keller Fabienne, Kelly Seán, Kennes Rudi, Khan Mary, Kircher Sophia, Knafo Sarah, Knotek Ondřej, Kobosko Michał, Köhler Stefan, Kohut Łukasz, Kokalari Arba, Kolář Ondřej, Kols Rihards, Konečná Kateřina, Kopacz Ewa, Körner Moritz, Kountoura Elena, Kovařík Ondřej, Kovatchev Andrey, Krištopans Vilis, Kruis Sebastian, Krutílek Ondřej, Kubín Tomáš, Kuhnke Alice, Kulja András Tivadar, Kulmuni Katri, Kyllönen Merja, Kyuchyuk Ilhan, Lakos Eszter, Lalucq Aurore, Lange Bernd, Langensiepen Katrin, Laššáková Judita, László András, Latinopoulou Afroditi, Laurent Murielle, Laureti Camilla, Laykova Rada, Lazarov Ilia, Le Callennec Isabelle, Leggeri Fabrice, Lenaers Jeroen, Leonardelli Julien, Lewandowski Janusz, Lexmann Miriam, Liese Peter, Loiseau Nathalie, Løkkegaard Morten, Lopatka Reinhold, López Javi, López Aguilar Juan Fernando, López-Istúriz White Antonio, Lövin Isabella, Lucano Mimmo, Luena César, Łukacijewska Elżbieta Katarzyna, Lupo Giuseppe, McAllister David, Madison Jaak, Maestre Cristina, Magoni Lara, Magyar Péter, Maij Marit, Maląg Marlena, Manda Claudiu, Mandl Lukas, Maniatis Yannis, Mantovani Mario, Maran Pierfrancesco, Marczułajtis-Walczak Jagna, Maréchal Marion, Mariani Thierry, Marino Ignazio Roberto, Marquardt Erik, Martín Frías Jorge, Martusciello Fulvio, Marzà Ibáñez Vicent, Mato Gabriel, Mavrides Costas, Maydell Eva, Mayer Georg, Mazurek Milan, Mažylis Liudas, McNamara Michael, Mebarek Nora, Meimarakis Vangelis, Meleti Eleonora, Mendes Ana Catarina, Mendia Idoia, Mertens Verena, Mesure Marina, Metsola Roberta, Metz Tilly, Mikser Sven, Milazzo Giuseppe, Millán Mon Francisco José, Minchev Nikola, Miranda Paz Ana, Molnár Csaba, Montero Irene, Montserrat Dolors, Morace Carolina, Morano Nadine, Moratti Letizia, Moreira de Sá Tiago, Moreno Sánchez Javier, Moretti Alessandra, Motreanu Dan-Ştefan, Mularczyk Arkadiusz, Müller Piotr, Mullooly Ciaran, Mureşan Siegfried, Muşoiu Ştefan, Nagyová Jana, Navarrete Rojas Fernando, Negrescu Victor, Nemec Matjaž, Nerudová Danuše, Nesci Denis, Neuhoff Hans, Neumann Hannah, Nevado del Campo Elena, Nica Dan, Niebler Angelika, Niedermayer Luděk, Niinistö Ville, Nikolaou-Alavanos Lefteris, Nikolic Aleksandar, Ní Mhurchú Cynthia, Noichl Maria, Nordqvist Rasmus, Novakov Andrey, Nykiel Mirosława, Obajtek Daniel, Ódor Ľudovít, Oetjen Jan-Christoph, Ohisalo Maria, Olivier Philippe, Omarjee Younous, Ondruš Branislav, Ó Ríordáin Aodhán, Orlando Leoluca, Ozdoba Jacek, Paet Urmas, Pajín Leire, Palmisano Valentina, Panayiotou Fidias, Papadakis Kostas, Papandreou Nikos, Pappas Nikos, Pascual de la Parte Nicolás, Patriciello Aldo, Paulus Jutta, Pedro Ana Miguel, Pedulla’ Gaetano, Pellerin-Carlin Thomas, Peltier Guillaume, Penkova Tsvetelina, Pennelle Gilles, Pereira Lídia, Peter-Hansen Kira Marie, Petrov Hristo, Picaro Michele, Picierno Pina, Picula Tonino, Piera Pascale, Pietikäinen Sirpa, Pimpie Pierre, Piperea Gheorghe, de la Pisa Carrión Margarita, Pokorná Jermanová Jaroslava, Polato Daniele, Polfjärd Jessica, Popescu Virgil-Daniel, Pozņaks Reinis, Prebilič Vladimir, Princi Giusi, Protas Jacek, Pürner Friedrich, Rackete Carola, Radev Emil, Radtke Dennis, Rafowicz Emma, Ratas Jüri, Razza Ruggero, Rechagneux Julie, Regner Evelyn, Repasi René, Repp Sabrina, Ressler Karlo, Reuten Thijs, Riba i Giner Diana, Ricci Matteo, Ridel Chloé, Riehl Nela, Ripa Manuela, Rodrigues André, Ros Sempere Marcos, Roth Neveďalová Katarína, Rougé André, Ruissen Bert-Jan, Ruotolo Sandro, Rzońca Bogdan, Saeidi Arash, Salini Massimiliano, Salis Ilaria, Salla Aura, Sánchez Amor Nacho, Sanchez Julien, Sancho Murillo Elena, Saramo Jussi, Sardone Silvia, Sargiacomo Eric, Satouri Mounir, Saudargas Paulius, Sbai Majdouline, Sberna Antonella, Schaldemose Christel, Schaller-Baross Ernő, Schenk Oliver, Scheuring-Wielgus Joanna, Schieder Andreas, Schilling Lena, Schneider Christine, Schnurrbusch Volker, Schwab Andreas, Scuderi Benedetta, Seekatz Ralf, Sell Alexander, Serrano Sierra Rosa, Sidl Günther, Sienkiewicz Bartłomiej, Sieper Lukas, Simon Sven, Singer Christine, Sinkevičius Virginijus, Sippel Birgit, Sjöstedt Jonas, Śmiszek Krzysztof, Smith Anthony, Smit Sander, Sokol Tomislav, Solier Diego, Solís Pérez Susana, Sommen Liesbet, Sonneborn Martin, Sorel Malika, Sousa Silva Hélder, Søvndal Villy, Squarta Marco, Staķis Mārtiņš, Stancanelli Raffaele, Ştefănuță Nicolae, Steger Petra, Stier Davor Ivo, Storm Kristoffer, Stöteler Sebastiaan, Stoyanov Stanislav, Strack-Zimmermann Marie-Agnes, Strada Cecilia, Streit Joachim, Strik Tineke, Strolenberg Anna, Sturdza Şerban Dimitrie, Stürgkh Anna, Sypniewski Marcin, Szczerba Michał, Szekeres Pál, Szydło Beata, Tamburrano Dario, Tânger Corrêa António, Tarczyński Dominik, Tarquinio Marco, Tarr Zoltán, Târziu Claudiu-Richard, Tavares Carla, Tegethoff Kai, Teodorescu Georgiana, Teodorescu Måwe Alice, Terheş Cristian, Ter Laak Ingeborg, Terras Riho, Tertsch Hermann, Thionnet Pierre-Romain, Timgren Beatrice, Tinagli Irene, Tobback Bruno, Tobé Tomas, Tolassy Rody, Tomac Eugen, Tomašič Zala, Tomaszewski Waldemar, Tomc Romana, Tonin Matej, Toom Jana, Torselli Francesco, Tosi Flavio, Toussaint Marie, Tovaglieri Isabella, Tridico Pasquale, Trochu Laurence, Tsiodras Dimitris, Tudose Mihai, Turek Filip, Tynkkynen Sebastian, Ušakovs Nils, Vaidere Inese, Valchev Ivaylo, Vălean Adina, Valet Matthieu, Van Brempt Kathleen, Van Brug Anouk, van den Berg Brigitte, Vandendriessche Tom, Van Dijck Kris, Van Lanschot Reinier, Van Leeuwen Jessika, Vannacci Roberto, Van Sparrentak Kim, Varaut Alexandre, Vasconcelos Ana, Vasile-Voiculescu Vlad, Vautmans Hilde, Vedrenne Marie-Pierre, Ventola Francesco, Verougstraete Yvan, Veryga Aurelijus, Vicsek Annamária, Vieira Catarina, Vigenin Kristian, Vilimsky Harald, Vincze Loránt, Vind Marianne, Vistisen Anders, Vivaldini Mariateresa, Volgin Petar, von der Schulenburg Michael, Vondra Alexandr, Voss Axel, Vozemberg-Vrionidi Elissavet, Vrecionová Veronika, Vázquez Lázara Adrián, Waitz Thomas, Walsh Maria, Walsmann Marion, Warborn Jörgen, Warnke Jan-Peter, Wąsik Maciej, Wawrykiewicz Michał, Wcisło Marta, Wechsler Andrea, Weimers Charlie, Werbrouck Séverine, Wiesner Emma, Wiezik Michal, Winkler Iuliu, Winzig Angelika, Wiseler-Lima Isabel, Wiśniewska Jadwiga, Wölken Tiemo, Wolters Lara, Yar Lucia, Yon-Courtin Stéphanie, Yoncheva Elena, Zacharia Maria, Zalewska Anna, Žalimas Dainius, Zan Alessandro, Zarzalejos Javier, Zdechovský Tomáš, Zdrojewski Bogdan Andrzej, Zijlstra Auke, Zīle Roberts, Zingaretti Nicola, Złotowski Kosma, Zver Milan

    Excused:

    Verheyen Sabine

    MIL OSI Europe News –

  • MIL-OSI Europe: Answer to a written question – Plans to centralise health policy powers at EU level – E-000666/2025(ASW)

    Source: European Parliament

    Various forms of centralised p rocurement of medical countermeasures create the possibility for participating Member States to benefit from collective bargaining power, and — in cases of limited supply — to avoid competition between Member States. This ensures equitable access to medical supplies and promotes cost efficiency.

    Should the participating Member States agree to the exclusivity of a centralised procurement, as was the case for COVID-19 (advanced) purchase agreements, this further strengthens their negotiation position.

    During preparedness mode, joint procurement of medical countermeasures is conducted by the Commission to enhance preparedness and response against serious cross-border health threats based on Regulation (EU) 2022/2371[1].

    This collaborative approach helps to reinforce the individual capabilities of each country while strengthening the overall resilience of the EU’s public health response mechanisms.

    Participation in joint procurement and other forms of centralised procurement is voluntary for the participating countries, thus fully preserving the competence of the Member States to organise their national health services and medical care, as prescribed by Article 168(7) Treaty on the Functioning of the European Union (TFEU).

    P ossible restrictions to parallel procurement and negotiation activities by the participating countries for the medical countermeasure in question are only possible if the Parties to the Joint Procurement Agreement agree to such restrictions.

    The division of competences between the Commission and the Member States is based on TFEU and remains unchanged. A recent Commission Communication[2] provides an overview of the actions undertaken in the area of health policy.

    • [1] Regulation (EU) 2022/2371 of the European Parliament and of the Council of 23 November 2022 on serious cross-border threats to health https://eur-lex.europa.eu/eli/reg/2022/2371/oj/eng
    • [2] Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions — The European Health Union: acting together for people’s health — https://commission.europa.eu/document/download/98c6e4dc-0fc3-4ec6-8ec2-bfcdcb2f018a_en?filename=policy_com-2024-206_en.pdf
    Last updated: 8 May 2025

    MIL OSI Europe News –

  • MIL-OSI United Kingdom: Latest data on listeriosis

    Source: United Kingdom – Executive Government & Departments

    News story

    Latest data on listeriosis

    The infection can cause severe illnesses in the elderly, immunocompromised or those with underlying chronic conditions.

    There were 179 cases of listeriosis reported in England and Wales in 2024, according to new data published today by the UK Health Security Agency (UKHSA).

    Listeriosis is caused by Listeria bacteria and is usually contracted by eating contaminated raw, chilled, or ready-to-eat foods. Most people with listeriosis won’t have any symptoms or will have mild gastroenteritis. However, the infection can cause severe illnesses in the elderly, immunocompromised or those with underlying chronic conditions. Infection during pregnancy can lead to miscarriage or stillbirth, or severe infections in newborn babies.

    The 179 cases reported in 2024 are comparable to the previous year’s figures (177 cases in 2023), and to levels seen in the years preceding the COVID-19 pandemic. The latest data show that while listeriosis can affect people of all ages, it poses a significantly greater risk to vulnerable groups, with the highest numbers seen in people aged 80 and over. Of the 28 deaths reported among 142 non-pregnancy cases, 12 were aged 80 years and over. Among pregnancy-associated infections, which accounted for approximately one-fifth of all cases, 43.7% resulted in stillbirth or miscarriage where outcomes were known.

    In England, London had the highest levels of listeriosis (0.39 cases per 100,000 population), whilst the East of England had the lowest (0.23 cases per 100,000 population).

    Vanessa Wong, UKHSA Consultant in gastrointestinal infections, said:

    Listeriosis is a rare infection and most people only experience mild symptoms of gastroenteritis that usually pass within a few days without the need for treatment. However, severe listeriosis is more likely to affect the elderly, very young babies, pregnant women and those with a weakened immune system. The best way to prevent listeriosis is to practise good food hygiene and avoid high-risk foods if you are in a vulnerable group. Foods that carry a greater risk of Listeria include: soft cheeses, pâté, smoked fish, chilled sliced meats and other chilled ready-to-eat products.

    Those at higher risk from severe Listeria infection include:

    • elderly people (risk increases with age)
    • those with malignancies or undergoing immunosuppressive or cytotoxic treatments
    • pregnant women and their unborn or newborn infants
    • organ transplant recipients
    • people with chronic kidney and liver diseases
    • those with uncontrolled diabetes, HIV, alcohol dependency or iron overload

    In most people, listeriosis has no symptoms or only causes mild symptoms for a few days, such as:

    • high temperature
    • aches and pains
    • chills
    • feeling or being sick
    • diarrhoea

    If you’re pregnant, you may also have a stomach ache or notice your baby moving less than usual.

    For advice on avoiding listeriosis during pregnancy or if you are in a high-risk group, please visit the NHS website at Listeriosis – NHS

    In 2024, UKHSA investigated 7 listeriosis outbreaks across England and Wales, linked to various food products including smoked fish, chocolate and strawberry mousse, garlic sausage and pre-packed sandwiches.

    Updates to this page

    Published 8 May 2025

    MIL OSI United Kingdom –

  • MIL-OSI: Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

    Source: GlobeNewswire (MIL-OSI)

    • Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025
    • District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendment
    • Fully enrolled Cohort A of ASCENT study in patients with PH-ILD
    • Further strengthened financial position via access of up to $100 million from existing financing agreement with HealthCare Royalty
    • Company to host webcast today at 8:30 a.m. ET

    MORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the first quarter ended March 31, 2025. The company will also host a webcast at 8:30 a.m. ET on May 8, 2025 to discuss its financial results and provide a corporate update.

    Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “With the FDA’s PDUFA goal date on the YUTREPIA NDA just over two weeks away, we remain focused on ensuring that we are prepared to make YUTREPIA commercially available in the quickest time possible if granted full approval. We continue to believe that YUTREPIA has the potential to be the prostacyclin of first choice for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).”

    Corporate Updates

    Awaiting FDA action on NDA for YUTREPIA (treprostinil) inhalation powder
    On March 28, 2025, the U.S. Food and Drug Administration (FDA) accepted Liquidia’s New Drug Application (NDA) resubmission for YUTREPIA (treprostinil) inhalation powder to treat PAH and PH-ILD as a complete Class 1 response to the previous action letter issued on August 16, 2024, which granted tentative approval of YUTREPIA. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025, the day after regulatory exclusivity expires for Tyvaso DPI®.

    Court will not hear cross-claim that challenged the amendment to the YUTREPIA NDA to add the PH-ILD indication
    On May 2, 2025, Liquidia announced that the U.S. District Court for the District of Columbia (District Court) dismissed, without prejudice, the cross-claim filed by United Therapeutics (UTHR) that sought to challenge Liquidia’s amendment to its NDA for YUTREPIA™ (treprostinil) inhalation powder, which added the treatment of PH-ILD)to the proposed label for YUTREPIA. In its ruling, the District Court determined that UTHR’s claim was unripe and that UTHR had failed to plausibly allege that it has standing. UTHR has the right to appeal the Court’s ruling.

    Fully enrolled Cohort A of ASCENT study in PH-ILD patients
    In March 2025, Liquidia completed enrollment of Cohort A of the open-label ASCENT study evaluating the tolerability and titratability of YUTREPIA in PH-ILD, with more than 50 patients enrolled. An interim look at the dosing and tolerability profile in the first 20 patients to complete eight weeks of treatment was consistent with observations made in the INSPIRE study of PAH patients. To date, patients in Cohort A of ASCENT were able to titrate to doses that are three-times higher than the labelled target dose of nebulized Tyvaso, while showing positive trends on exploratory measures of efficacy, including 6-minute walk distance. Liquidia will present additional data from Cohort A of the ASCENT study during two poster sessions at the American Thoracic Society (ATS) 2025 International Conference on May 21, 2025.

    Strengthened financial position ahead of launch via amendment to Agreement with HealthCare Royalty
    On March 17, 2025, Liquidia entered into a sixth amendment to its agreement with HealthCare Royalty (HCR Agreement) to provide for up to an additional $100 million of financing in three tranches. The company intends to use the proceeds to fund ongoing commercial development of YUTREPIA, continued development of YUTREPIA in other clinical trials, including but not limited to trials for pediatric patients and trials further evaluating the use of YUTREPIA in PAH and PH-ILD patients, clinical development of L606, a sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and for general corporate purposes.

    First Quarter 2025 Financial Results

    Cash and cash equivalents totaled $169.8 million as of March 31, 2025, compared to $176.5 million as of December 31, 2024.

    Revenue was $3.1 million for the three months ended March 31, 2025, compared to $3.0 million for the three months ended March 31, 2024. Revenue related primarily to the promotion agreement with Sandoz, Inc. pursuant to which we share profits from the sale of Treprostinil Injection in the United States (Promotion Agreement). The increase of $0.1 million was primarily due to the impact of unfavorable gross-to-net returns adjustments recorded in the prior year offset by lower sales volumes in the current year.

    Cost of revenue was $1.5 million for each of the three months ended March 31, 2025 and 2024. Cost of revenue related to the Promotion Agreement as noted above.

    Research and development expenses were $7.0 million for the three months ended March 31, 2025, compared to $10.1 million for the three months ended March 31, 2024. The decrease of $3.1 million or 31% was primarily due to a $3.6 million decrease in personnel expenses (including stock-based compensation) due to a shift from activities related to research and development to preparation for the potential commercialization of YUTREPIA. These decreases were offset by a $1.7 million increase in clinical expenses related to our L606 program, and a $0.4 million decrease in expenses related to our YUTREPIA research and development activities.

    General and administrative expenses were $30.1 million for the three months ended March 31, 2025, compared to $20.2 million for the three months ended March 31, 2024. The increase of $9.9 million or 48% was primarily due to a $8.1 million increase in personnel expenses (including stock-based compensation) driven by higher headcount and a shift from activities related to research and development to preparation for the potential commercialization of YUTREPIA, a $0.6 million increase in legal fees related to our ongoing YUTREPIA-related litigation, and a $0.6 million increase in facilities and infrastructure expenses.

    Total other expense, net was $2.9 million for the three months ended March 31, 2025, compared with $1.3 million for the three months ended March 31, 2024. The increase of $1.6 million was primarily driven by a $1.5 million increase in interest expense attributable to the higher borrowings under the HCR Agreement.

    Net loss for the three months ended March 31, 2025, was $38.4 million or $0.45 per basic and diluted share, compared to a net loss of $30.1 million, or $0.40 per basic and diluted share, for the three months ended March 31, 2024.

    About YUTREPIA™ (treprostinil) Inhalation Powder
    YUTREPIA is an investigational, inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. In August 2024, the FDA issued tentative approval of YUTREPIA for the PAH and PH-ILD indications. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from Tyvaso® (nebulized treprostinil). YUTREPIA is currently being studied in the ASCENT trial, an Open-Label Prospective Multicenter Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension, to evaluate the safety and tolerability of YUTREPIA in PH-ILD patients. YUTREPIA was previously referred to as LIQ861 in investigational studies.

    About L606 (liposomal treprostinil) Inhalation Suspension
    L606 is an investigational, sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer. The L606 suspension uses Pharmosa Biopharm’s proprietary liposomal formulation to encapsulate treprostinil which can be released slowly at a controlled rate into the lung, enhancing drug exposure over an extended period of time. L606 is currently being evaluated in an open-label study in the United States for treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) with a planned global pivotal placebo-controlled efficacy study for the treatment of PH-ILD.

    About Treprostinil Injection
    Treprostinil Injection is the first-to-file, fully substitutable generic treprostinil for parenteral administration. Treprostinil Injection contains the same active ingredient, same strengths, same dosage form and same inactive ingredients as Remodulin® (treprostinil) and is offered to patients and physicians with the same level of service and support, but at a lower price than the branded drug. Liquidia PAH promotes the appropriate use of Treprostinil Injection for the treatment of PAH in the United States in partnership with its commercial partner, Sandoz, who holds the Abbreviated New Drug Application (ANDA) with the FDA.

    About Pulmonary Arterial Hypertension (PAH)
    Pulmonary arterial hypertension (PAH) is a rare, chronic, progressive disease caused by hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death. Currently, an estimated 45,000 patients are diagnosed and treated in the United States. There is currently no cure for PAH, so the goals of existing treatments are to alleviate symptoms, maintain or improve functional class, delay disease progression and improve quality of life.

    About Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
    Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) includes a diverse collection of up to 150 different pulmonary diseases, including interstitial pulmonary fibrosis, chronic hypersensitivity pneumonitis, connective tissue disease-related ILD, and chronic pulmonary fibrosis with emphysema (CPFE) among others. Any level of PH in ILD patients is associated with poor 3-year survival. A current estimate of PH-ILD prevalence in the United States is greater than 60,000 patients, though actual prevalence in many of these underlying ILD diseases is not yet known due to factors including underdiagnosis and lack of approved treatments until March 2021 when inhaled treprostinil was first approved for this indication.

    About Liquidia Corporation
    Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).  The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

    Remodulin® and Tyvaso® are registered trademarks of United Therapeutics Corporation.

    Cautionary Statements Regarding Forward-Looking Statements
    This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines, including the potential for final FDA approval of the NDA for YUTREPIA, which may occur after the expiration of the exclusivity period of TYVASO DPI, if at all, the timelines or outcomes related to patent litigation with United Therapeutics in the U.S. District Court for the District of Delaware, litigation with United Therapeutics and FDA in the U.S. District Court for the District of Columbia or other litigation between Liquidia and United Therapeutics or others, including rehearings or appeals of decisions in any such proceedings, the issuance of patents by the USPTO and our ability to execute on our strategic or financial initiatives, the potential for additional funding under the HCR Agreement, our anticipated use of net proceeds funded under the HCR Agreement, our estimates regarding future expenses, capital requirements and needs for additional financing, and potential revenue and profitability of YUTREPIA, if approved, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The receipt of tentative approval of an NDA from the FDA is not determinative as to whether or when the FDA will grant final approval. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

    Financial Statement Revision

    During the three months ended March 31, 2025, we identified immaterial errors in our accounting treatment of the fourth and fifth amendments to the HCR Agreement.  We voluntarily revised our previously issued 2024 annual consolidated financial statements to correct the immaterial errors and disclosed the impacts to our quarterly financial statements for the respective 2024 interim periods in our Current Report on Form 8-K filed on May 8, 2025. As a result of the revision, the loss on extinguishment has been eliminated and an adjustment to interest expense resulting from the modifications has been recorded, with corresponding adjustments to the long-term debt and accumulated deficit accounts.  The financial statement line items as of and for the three months ended March 31, 2024 in the financial statements presented in this press release reflect such revisions.

    Contact Information

    Investors:
    Jason Adair
    Chief Business Officer
    919.328.4350
    Jason.adair@liquidia.com

    Media:
    Patrick Wallace
    Director, Corporate Communications
    919.328.4383
    patrick.wallace@liquidia.com

    Liquidia Corporation
    Select Condensed Consolidated Balance Sheet Data (unaudited)
    (in thousands)
                 
        March 31,     December 31,  
        2025     2024  
    Cash and cash equivalents   $ 169,758     $ 176,479  
    Total assets   $ 227,429     $ 230,313  
    Total liabilities   $ 177,716     $ 150,935  
    Accumulated deficit   $ (595,756 )   $ (557,389 )
    Total stockholders’ equity   $ 49,713     $ 79,378  
                 
    Liquidia Corporation
    Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)
    (in thousands, except share and per share amounts)
     
        Three Months Ended
    March 31,    		  
        2025     2024  
    Revenue   $ 3,120     $ 2,972  
    Costs and expenses:                
    Cost of revenue     1,517       1,467  
    Research and development     6,966       10,057  
    General and administrative     30,062       20,249  
    Total costs and expenses     38,545       31,773  
    Loss from operations     (35,425 )     (28,801 )
    Other income (expense):                
    Interest income     1,728       1,880  
    Interest expense     (4,670 )     (3,162 )
    Total other expense, net     (2,942 )     (1,282 )
    Net loss and comprehensive loss   $ (38,367 )   $ (30,083 )
    Net loss per common share, basic and diluted   $ (0.45 )   $ (0.40 )
    Weighted average common shares outstanding, basic and diluted     85,172,696       75,393,907  

    The MIL Network –

  • MIL-OSI United Kingdom: Register now for beauty and aesthetics webinar

    Source: City of Canterbury

    Home  »  Latest News   »   Register now for beauty and aesthetics webinar

    Local businesses in the skin piercing industry can sign up for a free webinar that sets out the latest developments within the sector.

    It takes place on Tuesday 13 May between 10am and midday, and our environmental health team is encouraging good attendance from relevant businesses in the district.

    The beauty and aesthetics webinar will cover:

    • Preparations for the forthcoming licensing scheme
    • Information around health and safety duty of care
    • Informed consent – what is it and what are your duties?
    • Prescription only medicines and pharmacy medicines

    Speakers include Registered Nurse and cosmetic medicine expert Andrew Rankin, Health and Safety Officer at Dartford Borough Council, Fleur Van Haeften, and Senior Infection Prevention and Control Specialist Nurse at UKHSA, Esther Taborn.

    Between them they will share their expert knowledge and provide invaluable advice to those working in this industry.

    This free webinar is open to businesses across Kent and is being led by Dartford Borough Council.

    To register attendance or to request additional topics and questions you’d like covered, email eh.admin@dartford.gov.uk.

    Published: 8 May 2025

    MIL OSI United Kingdom –

  • MIL-OSI Russia: Breaking News: China-Russia Relations Maintain Steady, Healthy, and Upward Momentum Thanks to Joint Efforts – Xi Jinping

    Translation. Region: Russian Federal

    Source: People’s Republic of China in Russian –

    Source: People’s Republic of China – State Council News

    Xinhua | 08. 05. 2025

    Keywords: Xi Jinping, efforts, maintain, Chairman of the People’s Republic of China, Russian relations, upward momentum, Chinese, healthy, urgently, within its own, distinctive features, time of negotiations, mutually beneficial cooperation, Thursday, parties, did

    MOSCOW, May 8 (Xinhua) — Chinese President Xi Jinping said here on Thursday that China-Russia relations have maintained a stable, healthy and upward momentum thanks to the joint efforts of both sides.

    He also noted the constant good-neighborliness, friendship and mutually beneficial cooperation as the distinctive features of bilateral relations.

    Xi Jinping made the statement during talks with Russian President Vladimir Putin as part of his state visit to Russia. –0–

    Source: Xinhua

    Breaking News: China-Russia Relations Maintain Steady, Healthy, and Upward Momentum Through Joint Efforts — Xi Jinping Breaking News: China-Russia Relations Maintain Steady, Healthy, and Upward Momentum Through Joint Efforts — Xi Jinping

    MIL OSI Russia News –

  • MIL-OSI Asia-Pac: PM Modi Chairs High-Level Meeting with Secretaries of Government of India

    Source: Government of India

    Posted On: 08 MAY 2025 2:17PM by PIB Delhi

    The Prime Minister today chaired a high-level meeting with Secretaries of various Ministries and Departments of the Government of India to review national preparedness and inter-ministerial coordination in light of recent developments concerning national security.

    PM Modi stressed the need for seamless coordination among ministries and agencies to uphold operational continuity and institutional resilience.

    PM reviewed the planning and preparation by ministries to deal with the current situation. 

    Secretaries have been directed to undertake a comprehensive review of their respective ministry’s operations and to ensure fool-proof functioning of essential systems, with special focus on readiness, emergency response, and internal communication protocols.

    Secretaries detailed their planning with a Whole of Government approach in the current situation.

    All ministries have identified their actionables in relation to the conflict and are strengthening processes. Ministries are ready to deal with all kinds of emerging situations.

    A range of issues were discussed during the meeting. These included, among others, strengthening of civil defence mechanisms, efforts to counter misinformation and fake news, and ensuring the security of critical infrastructure. Ministries were also advised to maintain close coordination with state authorities and ground-level institutions.

    The meeting was attended by the Cabinet Secretary, senior officials from the Prime Minister’s Office, and Secretaries from key ministries including Defence, Home Affairs, External Affairs, Information & Broadcasting, Power, Health, and Telecommunications.

    The Prime Minister called for continued alertness, institutional synergy, and clear communication as the nation navigates a sensitive period. He reaffirmed the government’s commitment to national security, operational preparedness, and citizen safety.

     

    ***

    MJPS/ST

    (Release ID: 2127669) Visitor Counter : 97

    MIL OSI Asia Pacific News –

  • MIL-OSI United Kingdom: Advanced tech boosts fight against animal and plant disease

    Source: United Kingdom – Government Statements

    Press release

    Advanced tech boosts fight against animal and plant disease

    £10 million in new Government funding for surveillance programme will further strengthen the country’s biosecurity to protect animals, plants, people and trade.

    The fight against pests and diseases, which can cost the UK economy billions of pounds, has been stepped up today (Thursday 8 May) with £10m of new funding announced for surveillance projects.

    The Genomics for Animal and Plant Disease Consortium (GAP-DC) project led by the Animal and Plant Health Agency will undertake surveillance across animal, plant and aquatic environments, using advanced genome sequencing technologies – a method that reads the complete genetic code of a living organism, including viruses, bacteria, fungi, or animals – to detect, identify and track pathogens with precision.

    For example, when avian influenza is found in UK poultry, genome sequencing can help confirm the virus type, trace its spread, and detect any mutations, supporting disease control measures.

    The UK faces significant and growing economic threats from pests and diseases affecting agriculture, livestock, and the environment. Invasive species alone cost the UK economy an estimated £4 billion annually, while plant pathogens and pests contribute to substantial crop losses.

    Ash dieback is predicated to cost £15 billion to the UK over coming decades and livestock disease such as avian influenza can have devastating financial and societal consequences, and has been estimated to cost the poultry meat sector more than £100m over a two-year period.

    APHA Interim Chief Executive Dr Jenny Stewart said:

    “Disease presents a significant risk to our farmers, global trade and human health.

    “This vital funding and collaboration with world leading experts will help APHA identify and tackle disease risk more effectively.

    “This research will lead to significantly advanced surveillance capabilities to protect UK borders from new and existing threats.”

    Research to be undertaken in collaboration with seven expert partners will include a focus on increasing the speed of pathogen detection at our borders, addressing new and re-emerging disease outbreaks, developing new strategies to control and mitigate endemic disease, and an improved approach to working with stakeholders and the community. It will also investigate disease spillover from wild animals and plants – when a virus moves from one species to other, such as the transmission of the COVID-19 virus from bats to humans.

    The £10 million of new funding provided by Defra and UK Research and Innovation (UKRI) will strengthen pathogen detection across the UK over the next two years and help protect the UK economy, as part of the Government’s Plan for Change.

    The announcement comes during National Plant Health Week (5-12 May 2025), an annual designated week of action to raise public awareness and engagement on how to keep our plants healthy, led by Defra in partnership with 32 organisations, including the Royal Horticultural Society, the Woodland Trust and the Horticultural Trades Association.

    Additional information:

    • APHA is an executive agency, sponsored by the Department for Environment, Food & Rural Affairs, the Welsh Government, and the Scottish Government, which employs around 3,600 staff, based at various sites across the UK.
    • The GAP-DC project will help APHA to get a better understanding of new sequencing technologies and platforms available in genomic surveillance so that we can test more effectively.
    • The project is supported by £7 million of funding from Defra and £3m from UKRI.
    • A full list of partners involved in the project is below:

    -Animal and Plant Health Agency (lead)

    • Defra

    • UKRI

    • Forest Research

    • Centre for Environment, Fisheries and Aquaculture Science (Cefas)

    • The Pirbright Institute

    • Fera Science

    • Royal Veterinary College

    • Forest Research Head of Pathology Dr Lisa Ward said:

    “Forest Research is internationally renowned for the provision of science, research, evidence, data and services for the support of sustainable forestry.

    “The genomic methods being developed under the GAP DC project are essential to future proof Forest Research’s work on monitoring the health of our trees by enhancing early pathogen detection, allowing rapid response and more effective disease control.”

    • Royal Veterinary College Vice Principal for Research and Innovation Professor Oliver Pybus said:

    “The Royal Veterinary College is pleased to contribute its expertise in infectious disease genomics and animal health to GAP-DC.

    “The consortium will further strengthen the UK’s position as a world-leader in genomic surveillance for animal and plant pathogens”

    • Cefas Animal and Human Health Science Lead Professor David Bass said:

    “Cefas, an Executive Agency of Defra, has diverse expertise in marine and freshwater science, working for healthy and productive oceans, seas, and rivers, and safe and sustainable seafood.

    “Genomic methods for pathogen surveillance and understanding the health of aquatic organisms are central to this mission, so we greatly value our participation in GAP-DC, and contributing to the UK’s excellence and innovation in pathogen genomics.”

    Updates to this page

    Published 8 May 2025

    MIL OSI United Kingdom –

  • MIL-OSI Economics: Samsung TV Plus To Exclusively Live Stream SMTOWN LIVE 2025 in L.A. Globally on New SMTOWN Channel

    Source: Samsung

     
    Samsung Electronics today announced that Samsung TV Plus, its free ad-supported streaming (FAST) service, will serve as the exclusive global livestream platform for SMTOWN LIVE 2025 in L.A., the landmark K-pop concert commemorating the 30th anniversary of SM Entertainment. The live broadcast will air on May 11, from Dignity Health Sports Park in Los Angeles, to audiences across 18 countries via Samsung TV Plus.
     
    This milestone collaboration with SM Entertainment — the powerhouse behind K-pop’s global rise — marks a significant moment for Samsung TV Plus as it continues to redefine how fans worldwide experience Korean content.
     
    “Through our partnership with SM Entertainment, we’re leveraging Samsung TV Plus’s technology to bring the richness of K-Content to more viewers than ever before,” said Yong Su Kim, Executive Vice President of the Visual Display Business at Samsung Electronics. “This global event marks a significant moment for K-Pop fans everywhere and we’re proud to broaden access to premium Korean content for audiences around the world.”
     
     
    Unprecedented Global Access to K-pop’s Biggest Stage
    SMTOWN LIVE 2025 in L.A. will feature a star-studded lineup of SM Entertainment’s leading artists, including TVXQ!, SUPER JUNIOR, SHINee (KEY, MINHO), EXO (SUHO, CHANYEOL, KAI), Red Velvet (IRENE, SEULGI, JOY), NCT 127, NCT DREAM, WayV, aespa, RIIZE, NCT WISH, Hearts2Hearts, SMTR25, and much more.
     
    In addition to beloved fan-favorite tracks, Samsung TV Plus will exclusively showcase live performances, including:
     
    The first US stage of “poppop” by NCT WISH, following their recent music show win
    The live performance of “Wait On Me” by EXO’s KAI, a chart-topping track that reached No.1 on iTunes in 30 regions and topped China’s QQ Music digital album chart
     
    These moments will be available only on Samsung TV Plus, providing fans in select countries with exclusive front-row access.
     
     
    Dedicated SMTOWN Channel Enhances the K-pop Viewing Experience
    To further elevate fan engagement, Samsung TV Plus has launched a dedicated SMTOWN Channel that offers:
     
    Full concert replays of SMTOWN LIVE 2025 in L.A.
    Music videos and curated content highlighting SM artists and the legacy of SM Entertainment
     
    The SMTOWN LIVE 2025 in L.A. replay will be available exclusively on Samsung TV Plus in select countries for a six-month period, further reinforcing the platform’s role as a premier global destination for K-pop content.
     
     
    A Growing Hub for Global K-Content
    Samsung TV Plus continues to grow as a global destination for Korean entertainment, offering over 4,000 hours of free-to-stream dramas, thrillers, romance, crime series, and music programming. Available on more than 630 million Samsung devices across 30 countries, the platform provides a seamless, ad-supported viewing experience to millions of users — no subscriptions or logins required.
     
    With the SMTOWN LIVE 2025 in L.A. partnership, Samsung TV Plus solidifies its leadership in global K-content distribution — expanding access, deepening fan connections, and bringing iconic Korean entertainment into more homes around the world.
     
    For more information on how to watch SMTOWN LIVE 2025 in L.A. and explore the full Samsung TV Plus offering, visit www.samsung.com.

    MIL OSI Economics –

  • MIL-OSI Europe: Chairpersonship Conference on Gender Equality: Building resilience through inclusion and empowerment

    Source: Organization for Security and Co-operation in Europe – OSCE

    Headline: Chairpersonship Conference on Gender Equality: Building resilience through inclusion and empowerment

    VIENNA, 8 May 2025 – Over 400 participants from across the OSCE gathered in Vienna for the “Building resilience through inclusion and empowerment” Conference on Gender Equality organized under Finland’s 2025 OSCE Chairpersonship on 6 and 7 May 2025.
    By hosting the conference, Finland encouraged OSCE participating States to uphold their commitments on gender equality, address challenges faced by women and girls due to unequal opportunities, discrimination, and persisting violence, and take collective action to foster inclusion and empowerment.
    “Promoting gender equality is not just about fairness—it is about resilience, security, and building stronger societies. As Chair, Finland calls on all OSCE participating States to take tangible action to ensure that women and girls have equal opportunities to participate, lead, and shape the future,” said Ambassador Vesa Häkkinen, Finland’s Permanent Representative to the OSCE and Chair of the Permanent Council.
    The conference featured discussions led by high-level speakers, including Mariana Betsa, Deputy Minister for Foreign Affairs of Ukraine and Laura Rissanen, State Secretary at the Ministry of Social Affairs and Health of Finland. Representatives from OSCE Structures and Institutions, international organizations, and civil society also participated in the discussions.
    Key sessions addressed current trends in gender equality: rethinking the Women, Peace and Security Agenda against multiplying crises, preventing gender-based violence, promoting equal opportunities in the digital era and engaging men and boys for gender equality. In line with Finland’s strong priority to support Ukraine, the conference also featured a special session on amplifying Ukrainian women’s voices.
    Launch of the OSCE-wide Women, Peace, and Security Roadmap
    As part of the conference, the Chairpersonship launched an OSCE-wide Roadmap for the effective implementation of Women, Peace, and Security (WPS) commitments. The Roadmap provides a comprehensive overview of the OSCE’s efforts in advancing the WPS agenda and guides participating States towards concrete action.
    “In the year of the 25th Anniversary of 1325, we wanted to use our Chairpersonship of the OSCE to showcase the good work of the OSCE on WPS. We chose to put focus on concrete action, and to provide participating States with practical ideas for doing more on WPS,” said Ambassador Vesa Häkkinen.

    MIL OSI Europe News –

  • MIL-OSI United Kingdom: Delivering our Plan for Change for workers

    Source: United Kingdom – Government Statements

    Speech

    Delivering our Plan for Change for workers

    The Health and Social Care Secretary Wes Streeting spoke at the Union of Shop, Distributive and Allied Workers (Usdaw) Annual Conference in Blackpool.

    It’s great to be here in Blackpool.

    Paddy (Lillis), you stood in the tradition of the greatest leaders of our movement, who believed it was not enough to walk through the streets demanding change, but that we had to walk through the corridors of power to deliver it.

    I also want to say thank you to Dave (McCrossen) for his leadership as Deputy General Secretary.

    Paddy, Dave, what you and your team have achieved in Usdaw is truly remarkable.

    Given the challenges facing retail and food distribution and the high turnover rates in the sector, maintaining your membership is a tough enough challenge, but with your leadership, Usdaw has grown. 

    With the switch to online shopping and the decline of our high streets, accelerated by the pandemic, others would have thrown in the towel. 

    Instead, your Retail Recovery Plan is helping the sector to come back stronger.

    Usdaw is an example to the trade union and labour movement:

    • to focus on the issues that matter most in the workplace
    • to keep our heads screwed on and our feet on the ground
    • to always champion the interests of working people

    Paddy, Dave, on behalf of everyone here and on behalf of the Prime Minister and the government, thank you for everything you’ve done for Usdaw and for our country.

    I’m also delighted to welcome Joanne as Usdaw’s new General Secretary. Joanne, you made history as Usdaw’s youngest regional secretary and now you’ve made history as the first woman to become general secretary – and the youngest, too!

    It’s clear the whole conference is excited to see what you do in the role. Congratulations and good luck! 

    I owe so much to Usdaw.

    [Redacted political content.]

    And having had my life saved by the NHS when I had kidney cancer at the age of 38, I can think of no better way of repaying the debt I owe to the NHS than by saving our National Health Service. 

    We should be in no doubt about the threat to our NHS.

    When we came into government, we took over an NHS going through the worst crisis in history:

    • waiting lists at historic highs
    • patient satisfaction at record lows
    • people struggling to see a GP
    • dental deserts in huge swathes of the country
    • ambulances not turning up on time
    • A&E departments full to bursting
    • doctors on picket lines, instead of the front line
    • that founding promise, that the NHS would always be there for us when we needed it, broken

    The NHS was broken.

    [Redacted political content.]

    Broken, but not beaten. Because every day there are amazing people delivering outstanding and compassionate care, despite all those challenges.

    Not beaten, because as Nye Bevan is often quoted as saying: “The NHS will last as long as there’s folk with faith left to fight for it.”

    Well, every day since I became Health Secretary, I’ve gone into work fighting for our NHS.

    To restore that basic founding principle that the NHS should always be there for us when we need it.

    With our Plan for Change, we’ve hit the ground running.

    As our first step, we promised 2 million more appointments in our first year.

    Promise made, promise kept:

    • we delivered our promise 7 months early and we’ve smashed our target – delivering not 2, but 3 million extra appointments since July and rising
    • we’ve got waiting lists down 6 months on the trot, including during peak winter pressures
    • we ended the strikes within 3 weeks and delivered an above-inflation pay rise for NHS staff
    • we’ve invested an extra £26 billion in health and care
    • we’ve recruited 1,500 more GPs – and agreed a GP contract for the first time since the pandemic
    • we’ve delivered the biggest investment to hospices in a generation
    • the biggest expansion of Carer’s Allowance since the 1970s
    • a massive boost for older and disabled people through the Disabled Facilities Grant
    • the biggest real-terms increase to the Public Health Grant in nearly a decade
    • we’ve given pharmacies the biggest funding uplift in a generation
    • and last week we froze prescription charges for the first time in years

    A lot done, but there is more to do:

    • our bill on smoking and vapes will protect children and the most vulnerable and make this generation of kids the first smoke-free generation
    • our Mental Health Bill will stop the disgraceful incarceration of learning disabled adults
    • the ban on junk food advertising targeted at children will be a first step in addressing the growing problem of childhood obesity
    • we are working with health unions, councils and employers to deliver the first ever fair pay agreement for social care staff
    • and Louise Casey is leading a Commission on Social Care which will finally get a grip on a system that is broken for too many families

    [Redacted political content.]

    We will always defend our NHS as a publicly funded, public service, free at the point of use, so that when you fall ill you never have to worry about the bill. 

    Our job is twofold.

    First, to get the NHS back on its feet and treating patients on time again.

    And second, to reform the service for the long-term, so it is fit for the future.

    This summer we will publish our 10 Year Plan for Health:

    • shifting the focus of healthcare out of hospital and into the community, with more investment in primary and community care  
    • bringing our analogue health service into the digital age, arming staff with modern equipment and cutting-edge technology
    • turning our sickness service into a preventative health service, to help people live well for longer and tackle the biggest killers

    This cannot be done by one man sat behind a desk in Whitehall. We will only succeed if this is a team effort, from the Prime Minister to the 1.5 million people who work in the health service. And the millions of us who use it taking the decisions needed to live healthier, more active lives.

    Mental health

    I know Usdaw have long campaigned on the impact poor mental health and stress can have at work. And your ‘It’s good to talk’ campaign is helping to overcome stigma and offering practical support to members who may be struggling.

    Failing to take mental health seriously doesn’t just have an enormous impact on people. Absences take their toll on businesses, our NHS and our economy as a whole. 

    In the NHS, we’re expanding talking therapies. Last year, we provided almost 70,000 people with the support they need at work, up more than 60% on the year before. 

    We know a timely intervention on mental health can save anguish and distress further down the line, and to deliver this we need to expand the mental health workforce so everyone can access the right people, with the right support, at the right time. 

    That’s why our manifesto promised an extra 8,500 mental health staff: tackling mental ill-health and the causes of mental ill-health. 

    New deal for working people

    Central to good health and good mental health are good jobs.

    So while I’m focused on fixing the foundations of our NHS, the whole government is working hard to deliver our manifesto promise to deliver the new deal for working people.

    [Redacted political content.]

    Last month, our landmark Plan to Make Work Pay passed the House of Commons. It will mean: 

    • jobs that are more secure and family friendly 
    • a real living wage people can live on 
    • going further and faster to close the gender pay gap 
    • sick pay for the lowest earners 
    • day one rights from unfair dismissal 
    • ending fire and rehire  
    • and banning exploitative zero-hour contracts once and for all 

    Conference, this will be the biggest upgrade of workers’ rights in a generation.  

    Campaigned for by Usdaw, delivered by this government. 

    Of course change – real change – takes time. As I said to Laura Kuenssberg on the BBC over the weekend, I’m pretty sure when I talk about falling waiting lists, there are people shouting at the telly: “What are you talking about? I’m still waiting!”

    Both things are true. Waiting lists are falling and are over 200,000 lower today than they were when we came into office. But if you’re one of 7 million cases still on the list, you’re not feeling it yet.

    Similarly, the decisions I took within weeks of taking office that allowed us to employ 1,500 GPs are making a difference, but there will still be people going bananas trying to get through at 8am tomorrow morning after the bank holiday.

    If the Chancellor were standing here today, she’d also report that interest rates have fallen 3 times and wages are finally rising above inflation. But that doesn’t wash away the cost of living crisis.

    People are really struggling at the moment.

    Not living, just surviving.

    It’s not good for our health and it’s not good for our country.

    We were elected with a simple promise: change.

    It won’t be enough for people to see it in the statistics – you need to feel it in your lives.

    Is my family better off?

    Is the NHS there for me when I need it?

    Do my kids attend good schools?

    Are my streets safe?

    Am I getting a fair wage for a hard day at work?

    [Redacted political content.]

    Those are the questions we as politicians need to help you as union reps answer. 

    I want all of you to know that, in government, all of us feel that pressure to deliver the change people voted for. We don’t want to let you or our country down. 

    [Redacted political content.]

    At the weekend, I asked people to give us the time we need to deliver as we grapple with an enormous breadth and depth of challenges.

    [Redacted political content.]

    But day by day, week by week, step by step, we will rebuild our economy, rebuild our public services and rebuild trust in politics.

    There’ll be bumps in the road and we won’t get everything right.

    [Redacted political content.]

    This government has already:

    • increased the National Living Wage and National Minimum Wage, giving over 3 million workers a pay rise
    • delivered breakfast clubs at 750 primary schools, so that they start the day with hungry minds instead of hungry bellies
    • scrapped the wasteful Rwanda scheme and launched our Border Security Command
    • overhauled apprenticeships through a new Growth and Skills Levy
    • and switched on Great British Energy

    We’re:

    • bringing the UK’s railways back into public ownership
    • banning no-fault evictions and introducing new protections for renters
    • delivering the New Deal for Working People
    • and cutting NHS waiting lists

    Lots done, so much more to do. 

    [Redacted political content.]

    Change has begun and the best is still to come.

    Thank you.

    Updates to this page

    Published 8 May 2025

    MIL OSI United Kingdom –

  • MIL-OSI United Kingdom: Families enjoy Go Walks launch

    Source: City of Coventry

    The city’s new Go Walks scheme has been launched, giving families the chance to explore their local area, improve their health and build stronger communities.

    The series of walks is based around the City’s Family Hubs that provide welcoming, safe spaces where children, young people and families can access services and help, while enjoying fun activities and building friendships.

    The launch which took place on the 25 April saw families set out on one of the walks at the Moat Family Hub, hosted by guest of honour, and much-loved children’s TV presenter, Gemma Hunt, an Ambassador for The Outdoor Guide Foundation.

    Gemma said: “Go Walks is brilliant for these wonderful Family Hubs in Coventry.

    “There are different walks you can go on with your families and they’re all really easily accessible for all ages, so breathe in the fresh air and get outdoors.”

    After enjoying the walk, local families gave the scheme the thumbs-up, with comments including:

    • “The walk was amazing and I enjoyed it. It helped with my mental health and wellbeing. I’ll do more walks. It was good to meet new people.”
    • “The walk was beautiful. I saw places I never knew were there and enjoyed ice cream and seeing Gemma Hunt.”
    • “The walk was very exciting and the trail map is good. It’s a healthy way of engaging the kids.”

    See photos from the day – Family Hubs launch Go Walks | Flickr.

    Go Walks is the result of a new partnership between the City Council and The Outdoor Guide – an organisation that strongly believes in the value of enjoying a healthy life outdoors – which has built a national network of walks throughout the UK in both cities and the countryside.

    The aim of the walks is to link residents with green spaces in their areas. Showing local families the amazing facilities right on their doorstep – from parks and woodland to social supermarkets, food banks, drop-in centres, places of worship, medical centres and primary schools.  This initiative delivers on our pledge to children and young people to help them be and feel healthy as part of Child Friendly Cov.

    As well as enabling residents to get to know their area better and see the numerous facilities and support on offer, the walks will also introduce new arrivals to the City to their neighbourhood and bring people together. Families will be able to connect with their local Family Hub and discover all the free activities and resources available for them.

    Cllr Patricia Seaman, Cabinet Member for Children and Young People, said: “The Go Walks scheme is a wonderful idea and you could see how valued they will be by the reaction of people at the launch.

    “They will bring people together, get people talking and build communities, and they will help many to enjoy more of our great city while getting a little healthier.”

    Cllr Kamran Caan, Cabinet Member for Public Health and Sport, said: “We all know how important exercise is for our mental and physical wellbeing, and the Go Walks are a great way to enjoy some gentle activity in the fresh air.

    “They are ideal for families to spend some time together and to take a few minutes to relax away from the everyday pressures. I am sure they will be a popular addition to our city.”

    To learn more about Go Walks, visit The Outdoor Guide’s website. To find out more about your local Family Hub offer please visit www.coventryfamilies.co.uk

    MIL OSI United Kingdom –

  • MIL-OSI Russia: The 28th Eurasian Economic Summit is dedicated to finding solutions to global problems

    Translation. Region: Russian Federal

    Source: People’s Republic of China in Russian – People’s Republic of China in Russian –

    Source: People’s Republic of China – State Council News

    ISTANBUL, May 8 (Xinhua) — The 28th Eurasian Economic Summit kicked off in Istanbul on Wednesday to discuss ways to address pressing global issues such as conflicts, climate change, economic inequality and migration.

    The two-day summit, themed “A More Humane World – Dialogue for a Livable World,” is organized by Istanbul-based Marmara Group Foundation for Strategic and Social Research.

    Foundation President Akkan Suver described the summit as a unique platform for promoting inclusive dialogue between representatives of different countries around the world.

    “In a world increasingly characterized by conflict and polarization, our theme, ‘Dialogue for a World Fit to Live in’, highlights the urgent need for civil society, reason and conscience to guide us towards peace and cooperation,” he said in his opening remarks.

    The summit includes a number of sessions, including “Ecology, Economy, Energy and Artificial Intelligence” and “International Health Cooperation”, which highlight the multifaceted approach needed to address global challenges.

    One of the main events of the summit will be a session on “Disaster-Resilient Cities”, where world leaders will consider ways to strengthen urban infrastructure and ensure resilience to the growing threat of natural disasters caused by climate change.

    In addition, the Peace and Dialogue session will explore new approaches to peacebuilding and create opportunities for constructive dialogue in an increasingly polarized world.

    The summit is attended by more than 300 politicians, diplomats, scientists and entrepreneurs from almost 50 countries. –0–

    MIL OSI Russia News –

  • MIL-OSI Russia: Happy birthday to academician Georgy Kleiner!

    Translation. Region: Russian Federal

    Source: State University of Management – Official website of the State –

    On May 8, the day before the 80th anniversary of the Great Victory, the State University of Management congratulates one of the leading economists of the university and all of Russia, head of the Department of Institutional Economics at the IEF SUMU, Corresponding Member of the Russian Academy of Sciences, Doctor of Economics, Professor Georgy Kleiner on his birthday.

    Of course, these are not all of his positions and titles. For now, it will be enough to say that Georgy Borisovich at one time developed the concept of multi-level strategic planning, created a school of modern system analysis of the real sector of the Russian economy, and laid the foundations of the theory of systemic economics. Over the past 15 years, Professor Kleiner has been one of the first in the citation rating of Russian economists according to the Russian Science Citation Index. And there is something to cite, because he has written about 850 different scientific papers. For more than a quarter of a century, the hero of today’s celebration has been working at the State University of Management and still speaks at conferences and his open lectures, sharing his extensive knowledge of economics and life experience.

    From the bottom of our hearts and the entire university, we would like to wish Georgy Borisovich good health, many years of productive scientific life, work activity and pleasant rest in moments of peace.

    Subscribe to the TG channel “Our GUU” Date of publication: 05/08/2025

    Please note: This information is raw content directly from the source of the information. It is exactly what the source states and does not reflect the position of MIL-OSI or its clients.

    MIL OSI Russia News –